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Abstract  87 
 88 
Background 89 
Inhaler usability and deposition differ between devices. Change of device may therefore 90 
impact clinical and economic outcomes.  91 
Objective 92 
We aimed to characterize clinical and economic asthma outcomes surrounding the change 93 
from a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) for fixed-dose 94 
combination inhaled corticosteroids/long-acting beta agonist (FDC ICS/LABA) treatment.   95 
Methods 96 
Three retrospective cohort sub-studies using 2010-2015 data from the Korean Health 97 
Insurance and Review Assessment (HIRA) database were performed. Asthma patients 98 
receiving a first FDC ICS/LABA pMDI after initially being on FDC ICS/LABA DPI were included. 99 
The following outcomes were assessed: (1) persistence of change to pMDI over 6 months; (2) 100 
clinical outcomes during the year following the change compared to the baseline year; (3) non-101 
inferiority comparison of costs and effectiveness between patients changing to a pMDI and 102 
matched patients that continued their DPI.  103 
Results 104 
Changing patients seem to represent a more severe sub-population. Fifty-eight % of patients 105 
(95%CI: 56-60) persisted with the change. Following the change in therapy, an increased 106 
proportion of patients remained free from severe exacerbations (58.3%) compared to the year 107 
prior (47.4%, p<0.001). Patients that changed to pMDIs had significantly less severe 108 
exacerbations, acute respiratory events and lower SABA inhaler average daily dose, but 109 
higher ICS average daily dose (all, p<0.05), compared to matched patients remaining on a 110 
DPI. Total costs were similar between patients that changed to pMDI therapy compared to 111 
those remaining on a DPI.  112 
Conclusion 113 
Changing from a DPI to a pMDI for FDC ICS/LABA asthma treatment can be as effective and 114 
cost-effective as remaining on a DPI.  115 
 116 
 117 
 118 
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Highlights box  119 
1. What is already known about this topic? 120 
Inhaler usability and deposition differ between devices, but real-life clinical differences after 121 
inhaler change in asthma patients are unknown. 122 
2. What does this article add to our knowledge? 123 
Generally, changing from a dry powder inhaler (DPI) to a pressurized metered-dose inhaler 124 
(pMDI) for fixed dose combination inhaled corticosteroids/long-acting beta agonist asthma 125 
treatment is at least as effective and cost-effective as remaining on a DPI.  126 
3. How does this study impact current management guidelines 127 
The majority of asthma patients can change from DPI to pMDI inhalers devices with 128 
maintenance of clinical effectiveness as well as cost-effectiveness, while for some patients 129 
additional management strategies are required. 130 
 131 
Key words (max 10): asthma, inhaler, dry powder inhaler, pressurized metered-dose inhaler, 132 
economic evaluation, cost-effectiveness  133 
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 135 
AE                     Adverse Event 
A&E Accident and Emergency 
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DPI Dry Powder Inhaler 
ED Emergency Department 
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FDC Fixed Dose Combination 
FP Fluticasone Propionate 
GERD Gastroesophageal Reflux Disease 
GINA Global Initiative for Asthma 
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LABA Long-Acting Beta2 Agonist 
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LTRA Leukotriene Receptor Antagonist 
LRTI Lower Respiratory Tract Infection 
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OR Odds Ratio 
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RCC Relative Change in Coefficient 
RDAC Risk Domain Asthma Control 
RR Rate Ratio 
SABA Short-Acting Beta2 Agonist 
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SMD Standardised Mean Difference  
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Introduction 137 
Asthma is a chronic inflammatory airway disease with increasing global prevalence and 138 
significant morbidity and mortality worldwide.1 In Korea, asthma is recognized as both a clinical 139 
as well as economic burden, with an estimated prevalence of 2.7% in the over 10-year old 140 
population.2 141 
The international Global Initiative for Asthma provides an evidence-based approach to asthma 142 
management, while national Korean guidelines have also been introduced.3,4 Both guidelines 143 
recommend inhaled corticosteroids (ICS) and ICS/long-acting beta agonist (LABA) 144 
combination therapy by an inhaled route of administration, dependent upon the treatment step 145 
required. Current inhaler devices available for ICS/LABA combination therapy include dry 146 
powder inhalers (DPIs) and pressurized metered-dose inhalers (pMDIs). Optimal delivery to 147 
the lung requires a different inhalation technique and breathing pattern for each device-type.5 148 
DPIs are breath-activated, requiring deep and forceful inhalation, while pMDIs require 149 
coordination of inhalation with actuation of the inhaler. Both devices types have been shown 150 
to be effective in controlled settings with patients trained on how to correctly use the device.6,7 151 
In daily practice however, incorrect inhaler technique is frequent and is associated with poor 152 
asthma control and reduced adherence.8-10 153 
In Korea, current prescribing patterns for ICS/LABA therapy are dominated by DPIs. However, 154 
pMDIs may be equally cost-effective7, and, in a real-world observational study, patients 155 
prescribed a fixed-dose combination (FDC) ICS/LABA delivered via pMDI were found more 156 
likely to achieve asthma control and treatment success as compared to those prescribed a 157 
DPI.11 Furthermore, the use of multiple mixed devices is associated with increased inhaler 158 
technique errors and decreased asthma control.12 Since the use of pMDI short-acting beta 159 
agonist (SABA) relievers are common among patients with asthma, use of controllers with the 160 
same type as the reliever device might improve health and economic outcomes by simplifying 161 
the process of learning inhaler technique and reducing confusion compared to patients being 162 
on mixed DPI and pMDI devices. 163 
The aim of this study is to evaluate real-life clinical effectiveness and cost outcomes of 164 
changing from a DPI to a pMDI for FDC ICS/LABA therapy in patients with asthma. 165 
  166 
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Methods 167 
 168 
Study design  169 
This was a retrospective cohort database study evaluating three outcomes (Figure 1).  170 
Outcome 1 (persistence with change): a 1-year baseline and a 6 months’ outcome period, 171 
designed to evaluate the proportion of asthma patients that persisted with collecting 172 
prescriptions of FDC ICS/LABA pMDI (including beclomethasone/formoterol, 173 
fluticasone/formoterol) after their initial change to this inhaler from a DPI (including 174 
fluticasone/salmeterol, budesonide/formoterol).  175 
Outcome 2 (pre-change vs post-change outcomes): a 1-year baseline characterisation of the  176 
cohort who received ≥2 separate FDC ICS/LABA pMDI prescriptions, and no prescription for 177 
a FDC ICS/LABA DPI, for a period of 1 year. Asthma outcomes during the 1-year outcome 178 
period were compared to those during the baseline year.  179 
Outcome 3 (changed vs non-changed matched cohort outcomes): a 1-year baseline 180 
characterisation and a 1-year outcome period. Asthma effectiveness and economic outcomes 181 
were compared between patients that changed to FDC ICS/LABA pMDI treatment and those 182 
that remained on FDC ICS/LABA DPI treatment.  183 
 184 
Data source 185 
For this study, data from the Korean Health Insurance Review and Assessment (HIRA) 186 
Service database were used. In South Korea, all patients have a mandatory and universal 187 
health plan. The HIRA database covers the complete medical healthcare utilisation data for 188 
the entire population of South Korea (>50 million people). It provides a unique and unbiased 189 
overview of healthcare utilisation (including almost all primary care, pharmacy and hospital 190 
data) on a national level. The HIRA database has been extensively described13 and has been 191 
used in several previous studies including respiratory research.14-16 For this study, HIRA data 192 
from January 2010 to December 2015 were accessed.  193 
 194 
Inclusion and exclusion criteria 195 
The following general inclusion criteria were applied for all three outcomes: (i) aged 12-80 196 
years at date of first prescription for FDC ICS/LABA pMDI, (ii) at least 1 year baseline 197 
electronic medical records available, (iii) actively treated asthma, defined as ≥ 2 198 
prescriptions (prescribed on different dates) for FDC ICS/LABA DPI during the baseline year 199 
and (iv) same ICS daily fluticasone Propionate equivalent dose [based on GINA: low 200 
(>100μg & ≤250μg), medium (>250μg & ≤500μg), high (≥500μg)] at last prescription for FDC 201 
ICS/LABA DPI at baseline and prescription of FDC ICS/LABA at index date. We excluded 202 
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patients with the following criteria: (i) prescription of FDC ICS/LABA pMDI prior to study 203 
period, (ii) received maintenance oral corticosteroids (defined as ≥5 prescriptions of ≤10mg 204 
prednisolone-equivalent oral corticosteroids during the baseline year) and (iii) received 205 
multiple different types of FDC ICS/LABA or separate ICS or LABA prescriptions at index 206 
date. In addition, several outcome specific inclusion and exclusion criteria were applied 207 
(Appendix 1). 208 
 209 
[FIGURE 1] 210 
 211 
For each of the three study outcomes, one primary and multiple secondary exploratory clinical 212 
and cost endpoints were defined.  213 
 214 
Primary clinical outcomes 215 
Outcome 1 was persisting with change, defined as: percentage of ICS/LABA pMDI patients 216 
who, at 6 months post-index date, received ≥1 prescription of ICS/LABA pMDI (in addition to 217 
that issued at their prescription date) and no prescription for an ICS/LABA DPI over the same 218 
period. Patient characteristics of those that persisted with the change were compared to those 219 
not persisting with the change. A sub-analysis was performed to assess the number of patients 220 
remaining on the same pMDI device-drug combination while having no DPI prescriptions AND 221 
no other pMDI prescriptions.  222 
Outcome 2 was a non-inferiority assessment powered on the “no-exacerbation” endpoint 223 
defined as: the proportion of patients prescribed ≥2 FDC ICS/LABA pMDIs who had no severe 224 
exacerbations within 1 year of changing from a FDC ICS/LABA DPI device, compared to the 225 
baseline year. Non-inferiority was claimed if the lower limit of the 95% confidence interval (CI) 226 
of the mean difference in patient proportions with no severe exacerbations (outcome year – 227 
baseline year) was ≥ -0.125. 228 
Outcome 3 was a non-inferiority assessment powered on the “no-exacerbation” endpoint 229 
defined as: the proportion of patients prescribed ≥2 FDC ICS/LABA pMDIs who had no severe 230 
exacerbations within 1 year of changing from a FDC ICS/LABA DPI, compared to the repeat 231 
cohort that remained on FDC ICS/LABA DPI treatment. Notably, patients with no severe 232 
exacerbations, as defined by the ATS/ERS Task Force 2015, had the absence of asthma-233 
related hospital admissions, Accident & Emergency (A&E) attendances and acute courses of 234 
oral corticosteroids. Non-inferiority was claimed if the lower limit of the 95%CI of the mean 235 
difference (between change to pMDI and repeat DPI cohort) in patient proportions with no 236 
severe exacerbations in the outcome year was ≥-0.10. Note that this criterion for outcome 3 237 
was stricter than the one for outcome 2 given that this was a between-group comparison and 238 
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outcome 2 was a within-group comparison (where usually larger differences are observed). 239 
 240 
Secondary outcomes  241 
The following secondary exploratory endpoints were investigated for outcomes 2 and 3: 242 
severe asthma exacerbation rate, acute respiratory events, risk domain asthma control 243 
(RDAC), overall asthma control (OAC), treatment stability, asthma exacerbation-related 244 
hospitalization rate, average daily SABA usage, average daily ICS dose and incidence of oral 245 
thrush. Their exact definitions are specified in appendix 2. 246 
 247 
Cost outcomes 248 
Exploratory cost outcomes, assessed as part of outcome 3, included change in asthma-related 249 
costs such as asthma medication prescriptions (ICS/LABA, ICS, LABA, SABA/SAMA, 250 
LABA/LAMA, SABA, short-acting muscarinic antagonists [SAMA], long-acting muscarinic 251 
antagonists [LAMA], leukotriene receptor antagonists [LTRA], theophylline, acute oral 252 
corticosteroids and antibiotics for lower respiratory tract infections [LRTIs]), respiratory-related 253 
hospital costs, inpatient hospitalisation costs, outpatient hospitalization costs and A&E costs. 254 
Sample size calculations 255 
For outcome 1, a sample size of 100 patients was sufficient to construct a 95% one-sided 256 
confidence interval with an upper bound of less than 0.30 (30%) to power the evaluation of 257 
ICS/LABA pMDI “persistence of change”. For outcome 2, at N=163, a paired McNemar’s Chi-258 
square test with a 0.025 one-sided significance level has 90% power to reject the null 259 
hypothesis that the proportions are non-inferior when the expected difference in proportions 260 
is 0.0, assuming that the proportion of discordant pairs is 0.242. For outcome 3, when the 261 
sample sizes in the groups are 208 and 208, a two-group large-sample normal approximation 262 
test of proportions with a one-sided 0.025 significance level has 90% power to reject the null 263 
hypothesis that the proportions are non-inferior. 264 
 265 
Statistical analyses 266 
A characterisation of all baseline demographics, co-morbidities, disease severity and other 267 
patient characteristics was performed and presented for each arm. The difference between 268 
the arms was quantified using the Standardised Mean Difference (SMD). This measure is not 269 
affected by the number of observations, and is thus a better way to judge imbalance than a p-270 
value of a hypothesis test of difference.17 The SMD was calculated for both continuous and 271 
categorical variables: an SMD ≤0.1 indicates sufficient balance between the treatment and the 272 
reference groups.18 Bias potential was measured using the relative change in co-efficient 273 
(RCC) of the exposure when the covariate was added into the model predicting outcome. 274 
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Conditional regression analysis was performed on the matched dataset, taking into account 275 
the matched pairs. The type of regression used was dependent upon the outcome: linear 276 
regression for a continuous outcome, logistic regression for a binary outcome, Poisson 277 
regression for rates and proportional hazards regression for a time-to-event outcome. 278 
Adjustment for variables with residual confounding was made.  279 
All statistical analyses were conducted using SAS Enterprise Guide 6.1 (SAS Institute, 280 
Cary, North Carolina, USA). Statistically significant results were defined as P<.05. The 281 
statistical tests used in the analysis are summarized in appendix 3 and the full statistical plan 282 
including detailed sample size calculations, baseline characterisation, bias assessment, 283 
matching process and analyses is provided in appendix 4. 284 
Ethical approval 285 
This study was approved by the institutional review board of Konkuk University Hospital, 286 
Korea, with registration number KUH1010751. The study was registered at the European 287 
Network of Centres for Pharmacoepidemiology and Pharmacovigilance website with 288 
registration number EUPAS12275. 289 
 290 
  291 
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Results 292 
 293 
Outcome 1: persistence of change to pMDI 294 
In total, 1991 patients fulfilled our inclusion criteria. A patient flow diagram for the patient 295 
selection process is provided in appendix 5. During the 6-month outcome period, n=1152 296 
(57.9%) of patients received ≥1 prescription for FDC ICS/LABA pMDI, in addition to that issued 297 
at the index date, and no FDC ICS/LABA DPI prescriptions (Table 1). In total, n=1128 (56.7%) 298 
of patients that persisted with the change to FDC ICS/LABA pMDI treatment remained on the 299 
same device over the 6 months (Table 1). 300 
[TABLE 1] 301 
 302 
The full patient population details are provided in appendix 5. Overall, patients within the 303 
“persistence of change” group were statistically younger (i.e. 1.8 years) and had a different 304 
distribution of insurance-type compared to those who did not persist with the change to FDC 305 
ICS/LABA pMDI. The distribution of comorbidities was found to be similar for both groups, 306 
except for comorbid gastroesophageal reflux disease (GERD), which was higher in patients 307 
that did not persist with the change from a DPI to a pMDI. Oral thrush, influenza and nasal 308 
polyps were rarely recorded. In terms of disease severity, patients that persisted with the 309 
change to FDC ICS/LABA pMDI treatment had less inpatient admissions, outpatient visits and 310 
emergency visits than non-persistent patients during the baseline year. Persistent patients 311 
also had less severe exacerbations and acute respiratory events compared to those that failed 312 
with the change in therapy. During the baseline year, patients that successfully changed to 313 
pMDI treatment had fewer FDC ICS/LABA, IV/IM corticosteroid, SABA and theophylline (or 314 
other methylxanthine) prescriptions and decreased average ICS daily dose. A lower 315 
percentage of patients within the persistence of change group were prescribed SAMA, 316 
however the mean number of SAMA prescriptions was higher for these patients than for those 317 
that did not persist with the change. Non-persistent patients were found to have increased 318 
LAMA prescriptions during the baseline year, as compared to patients that persisted with the 319 
change to a pMDI inhaler. 320 
 321 
Outcome 2: 1-year pre versus 1-year post-change outcomes 322 
In total, 667 patients met the inclusion criteria for this outcome. They represented a population 323 
that was treated with a DPI for at least one year, was switched (for unknown reasons) to a 324 
pMDI and subsequently followed for one year. A patient flow diagram and full baseline patient 325 
characteristics are provided in appendix 6. Briefly, mean age of the population was 58.1 years 326 
12 
 
 
(SD: 15.1), 54.9% was male, mean (SD) number of all-cause admissions was 0.9 (1.8) of 327 
which 0.2 (0.8) asthma-related admissions, mean (SD) number of FDC ICS/LABA 328 
prescriptions was 4.7 (2.7) with mean (SD) ICS dose of 400.8 µg (279.3) and mean number 329 
of SABA inhalers was 1.8 (4.2).  330 
Non-inferiority of effectiveness (i.e. the proportion of patients free from exacerbations) during 331 
the outcome year (n=389; 58.3%) was determined for the population that changed from DPI 332 
to FDC ICS/LABA pMDI therapy as compared to the year prior to the change (n=316; 47.4%). 333 
Results indicated that the non-inferiority criterion was met (Table 2). 334 
[TABLE 2] 335 
 336 
The number of severe exacerbations (RR [95%CI] 1.56 [1.31, 1.86]) and acute respiratory 337 
events (RR [95%CI] 1.31 [1.14, 1.50]) were found (appendix 6, table A7) to have increased in 338 
the year following the change from a DPI to a pMDI for FDC ICS/LABA therapy, as compared 339 
to the year prior. Statistical significance for both outcomes was driven by an increase in the 340 
proportion of patients experiencing ≥2 severe exacerbations (7.9% vs 1.0%) or ≥3 acute 341 
respiratory events (14.5% vs 7.5%). However, an increased proportion of patients remained 342 
free from severe exacerbations (58.3%) or acute respiratory events (45.3%) during the year 343 
following the change to a pMDI as compared to during the baseline year (47.4% and 32.8% 344 
respectively).  345 
The proportion of patients that achieved overall asthma control was significantly increased 346 
during the outcome year as compared to the baseline year (P=.024, OR [95%CI] 1.18 [1.02, 347 
1.37]), reflecting the decreased average SABA daily dose following change of inhaler device 348 
(P<.001, OR [95%CI] 0.51 [0.43, 0.59]). Incidence of oral thrush was low and found to be 349 
decreased during the outcome year (OR [95%CI] 0.35 [0.14, 0.88]) as compared to the year 350 
prior to the change to pMDI therapy. In total, 41% of patients that changed to FDC ICS/LABA 351 
pMDI attained treatment stability.  352 
 353 
Outcome 3: changed versus non-changed cohort outcomes 354 
Based on SMD and clinical judgement, the 667 patients  that changed from DPI to pMDI 355 
(identified for outcome 2) were matched to patients continuing on DPI based on baseline 356 
variables age, gender, COPD diagnosis, categorised SABA average daily dose, categorised 357 
ICS average daily dose and categorised ERS/ATS exacerbations.19 Patients were then 358 
randomly picked with a maximum of 1:3 matching. The final cohort consisted of 642 FDC 359 
ICS/LABA pMDI “changed” patients and 1926 FDC ICS/LABA “repeat” DPI patients. Consort 360 
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diagram, full patient demographics, comorbidities, disease severity, prescribed medication 361 
and other characteristics are described in appendix 7. 362 
Following matching, patients in the DPI repeat and pMDI change cohorts were similar in age 363 
and gender (appendix 7, Table A8). Comorbidities were also matching between cohorts, with 364 
the exception of COPD (ever), oral thrush (ever), GERD, influenza, other respiratory disease 365 
and rhinitis having a high SMD. However, bias (RCC) for each of these indications was less 366 
than 2% and variables were therefore not candidates for adjustment. Disease severity 367 
distributions during the baseline year were found to be similar between the pMDI change and 368 
the DPI continuation cohorts after matching, apart from antibiotic use, which was deemed a 369 
candidate for adjustment. Asthma-related medication prescribed during the baseline year was 370 
also similar in terms of SMD for both cohorts following matching, except for ICS, SABA 371 
nebuliser, LABA, SAMA and LTRA prescriptions. SAMA and LTRA prescriptions were deemed 372 
candidates for adjustment. Asthma-related costs during the baseline year for the matched 373 
pMDI change and DPI repeat cohorts were similar and no cost variables were candidates for 374 
adjustment.  375 
Clinical outcomes 376 
The primary outcome, i.e. non-inferiority of effectiveness, with regards the proportion of 377 
patients that remained free from severe exacerbations during the outcome year, was met for 378 
the matched cohorts. Superiority was not met and the sample size requirements to enable 379 
demonstration of superiority were not achieved (Table 3).  380 
[TABLE 3] 381 
 382 
Secondary exploratory outcomes were compared between patients changing to a pMDI and 383 
those that repeated their DPI during the outcome year (Figure 2, appendix 7). Patients 384 
changing to pMDI had significantly less severe exacerbations (P=.015, RR [95%CI] 0.79 [0.65, 385 
0.95]) and acute respiratory events (P=.018, RR [95%CI] 0.84 [0.73, 0.97]), lower SABA 386 
inhaler average daily dose (P<.001, OR [95%CI] 0.71 [0.61, 0.84]) and higher ICS average 387 
daily dose category (P<.001, OR [95%CI] 1.57 [1.35, 1.81]) as compared to patients 388 
continuing with DPI treatment.  389 
[FIGURE 2] 390 
 391 
Cost outcomes 392 
Asthma-related cost outcomes during the year following index date were compared and 393 
presented in Table 4. Patients that changed to a pMDI incurred lower costs for FDC ICS/LABA 394 
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(P=.027), oral (P=.014) and inhaled (P<.001) SABA and oral LABA (P=.002) treatment and 395 
higher costs for leukotriene receptor antagonist treatment (P<.001) compared to those that 396 
continued with a DPI inhaler. The DPI group had higher medication cost, but slightly (non-397 
significantly) lower hospital costs. Total treatment costs over the outcome year were similar 398 
between patients that changed to FDC ICS/LABA pMDI therapy compared to those remaining 399 
on a DPI (KRW 2,073,305 versus KRW 1,927,458 respectively, P=0.451).  400 
[TABLE 4] 401 
 402 
Discussion 403 
Main findings 404 
This study aimed to characterize clinical asthma outcomes and assess the economic effects 405 
surrounding the change of inhaler from a DPI to a pMDI for ICS/LABA treatment in real-life 406 
Korean practice. A historical cohort study with three outcomes was performed using data 407 
extracted from the HIRA database. Generally, patients who changed inhaler seem to represent 408 
a sub-population with more uncontrolled asthma. In summary, in total, 58% of patients that 409 
changed inhaler from a DPI to a pMDI persisted with the change over 6 months. The remaining 410 
group of patients did not seem to receive benefit from the change in inhalers leading to failure 411 
of persistence with the switch. In persistent changers, the year following the change from a 412 
DPI to a pMDI for FDC ICS/LABA therapy was associated with increased asthma control, 413 
decreased acute respiratory events and decreased severe exacerbations. Changing to a pMDI 414 
for ICS/LABA therapy in patients with asthma was found to be associated with similar costs 415 
as remaining on a DPI. Finally, the results of this study showed that changing from a DPI to a 416 
pMDI inhaler for FDC ICS/LABA asthma treatment is associated with non-inferior 417 
effectiveness, compared to remaining on a DPI, in terms of exacerbation prevention. Yet, 418 
following the change, higher ICS doses were observed. In summary, for the majority of asthma 419 
patients, these results indicate equal effectiveness regarding asthma outcomes following the 420 
change from a DPI to a pMDI. 421 
Interpretation 422 
Overall results of this study are in line with previous reviews that indicated no differences 423 
between inhaler devices regarding clinical efficacy.6,7 Yet, looking deeper into the 424 
characteristics of the patients whose medication was changed, they may represent a more 425 
uncontrolled sub-population based on severity and possibly on the match of inhaler to patient. 426 
When physicians confront patients with uncontrolled asthma in daily practice, they apply 427 
multiple strategies of which some are performed alongside each other, including increasing 428 
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the ICS dose, enhancing adherence, adding drugs, switching or better matching of inhalers 429 
(such as aligning device types for rescue and maintenance medication). Patients who persist 430 
with the switch overall do better in terms of exacerbations, overall control, decreased SABA 431 
use, but a subgroup, presumably with more severe and uncontrolled asthma, experience 432 
worse outcomes such as more frequent exacerbations. In this subgroup, switching inhalers 433 
was apparently not (sufficiently) effective and patients may have been switched back to their 434 
original inhaler and/or had step-up treatment with e.g. biologicals.  435 
Notably, an important determinant for switch success may have been the guidance patients 436 
received during their switch. There are a few previous studies that specifically focused on the 437 
impact of device switching in asthma patients. A UK-based study (N=824) looked at patients 438 
(6-65 years) that switched ICS-containing devices without consulting their GP.20 Over half of 439 
the switches (53%) involved a switch from DPIs to pMDIs. It was found that patients that 440 
switched without GP consultation had worse asthma control as defined by SABA use, oral 441 
steroids use and hospitalizations. Direct comparison with this study is difficult given the fact 442 
that in our study, no distinction could be made between patients that had or did not have a 443 
consultation at the day of device switching. In addition, we used a higher age criterion thereby 444 
excluding younger children that may have more difficulties in switching. Results from this study 445 
do highlight the importance of close guidance and monitoring during the switch. Notably, from 446 
the patient perspective, there are indications that a non-consented switch may reduce patients’ 447 
relationship with their doctor, confidence in their medication and control over their asthma.21 448 
The finding of a higher ICS dose after changing to pMDIs deserves a comment. We 449 
hypothesize that the physician’s decision for changing devices may be partly driven by asthma 450 
control. Loss of control may have been tackled by both better matching and device and patient 451 
as well as increasing ICS dose. 452 
 453 
Strengths and limitations  454 
The strength of the study is that it is based on real-life data, obtained from a high-quality 455 
database reflective of the total population of South Korea that includes all medical resource 456 
utilization and cost data.13 To the best of our knowledge, this is the first nationwide study that 457 
shows the effects of changing from a DPI to a pMDI. The retrospective nature of this study 458 
means that patients were not influenced in any way and reduces recall bias. The datasets 459 
represent information collected for clinical and routine use, rather than specifically for research 460 
purposes. The validity and completeness of individual patient records cannot be assessed; as 461 
such there may be omissions or errors. Specific limitations were that the database did not 462 
provide any specific reasons for changing inhalers, did not provide data on exact daily SABA 463 
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usage as possible indication for the occurrence of non-severe exacerbations and no indirect 464 
cost data.22 A limitation of all observational studies is the possibility of confounding of the 465 
results, arising from systematic differences between the patients being compared. In this 466 
study, confounding was minimised where possible by fitting multivariate models which were 467 
adjusted by clinical variables and patient characteristics that varied between patient groups. 468 
Despite the measures taken, confounding by unmeasured variables (such as adherence to 469 
medication) may be present. This study looks solely at the use of FDC ICS/LABA inhalers and 470 
does not include/exclude patients by asthma or COPD diagnosis or use of a spacer. It is also 471 
noted that some asthma drugs are prescribed with COPD as a diagnosis due to strict 472 
reimbursement criteria in Korea. Having COPD as an exclusion criterion would, however, 473 
unnecessarily exclude asthma patients who are prescribed drugs affected by these 474 
reimbursement criteria.  475 
Implications for clinical practice, policy and future research 476 
While the data from this study indicate that FDC ICS/LABA device switching could be done 477 
without compromised asthma treatment effectiveness, in practice this switch should always 478 
be supervised and guided by an experienced physician. Reasons for switching should be 479 
properly explained to the patient23 and for patients with insufficient breath-hand coordination, 480 
pMDIs should always be co-prescribed with a spacer. Moreover, inhaler instructions for the 481 
new device are essential and should preferably be repeated periodically.24-26 Generally, 482 
prescribers of asthma inhalers should aim to match the device to patients’ preferences, 483 
capacities and needs.27 In addition, they should strive for uniformity of devices, including a 484 
good match between controller and reliever device handling characteristics. We recommend 485 
future studies aiming to confirm our findings by the means of prospective, randomized study 486 
designs including cost-effectiveness assessments. Furthermore, more studies focusing on the 487 
switch from pMDIs to DPIs, and their specific subtypes, should be performed. Showing no 488 
difference in outcomes regardless of the direction of the switch would convincingly fulfill their 489 
objective of showing that there is no difference between DPI and pMDIs. Lastly, the Korean 490 
healthcare system is unique and differs from other countries. In order to generalize the results 491 
of this study, validation studies in other countries are mandatory. 492 
Conclusion 493 
In real-life Korean practice, changing from a DPI to a pMDI for FDC ICS/LABA asthma 494 
treatment is as effective and cost-effective as remaining on a DPI. Taking into account patient 495 
subgroup characteristics and careful guidance surrounding the change are warranted.  496 
Role of the funding source 497 
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Figure legends 590 
 591 
 592 
[FIGURE 1] 593 
DPI: dry powder inhaler; FDC: fixed-dose combination; ICS/LABA: inhaled corticosteroids/long-acting beta agonist; 594 
pMDI: pressurized metered-dose inhaler; Rx: prescription 595 
Figure 1: Study design for outcomes 1, 2, and 3 596 
 597 
 598 
[FIGURE 2] 599 
CI: confidence interval; DPI: dry powder inhaler; ICS: inhaled corticosteroids; pMDI: pressurized metered dose 600 
inhaler; SABA: short-acting beta agonist 601 
Figure 2: Outcomes comparison between DPI repeat (M=1926) and pMDI change (N=642) 602 
cohort 603 
 604 
Repository tables 
 
Table A1: Outcome specific inclusion criteria 
Inclusion criteria (outcome 1 specific) 
 ≥1 prescription of FDC ICS/LABA during outcome period 
 Index date pMDI prescription between January 2010 to December 2015 (1 year baseline, 6 
months outcome) 
Inclusion criteria (outcome 2 specific) 
 ≥2 prescriptions of FDC ICS/LABA pMDI (prescribed on different dates) during outcome 
period 
 Index date pMDI prescription between January 2010 to December 2015 (1 year baseline, 1 
year outcome) 
Exclusion criteria (outcome 2 specific) 
 Prescription of FDC ICS/LABA DPI during outcome period 
Inclusion criteria (ouicome 3 specific) 
 ≥2 prescriptions of FDC ICS/LABA pMDI/DPI (change arm/repeat arm), prescribed on 
different dates, during outcome period 
 Index date pMDI/matched DPI prescription between January 2010 to December 2015 (1 year 
baseline, 1 year outcome) 
Exclusion criteria (outcome 3 specific) 
 Change of FDC ICS/LABA inhaler-type during outcome period 
 
  
Table A2: Statistical tests 
Statistical test Variable type Distribution 
Groups 
compared Data type 
Mann-Whitney (Wilcoxon rank 
sum) Continuous not normal 2 Independent 
Kruskal-Wallis test Continuous not normal >2 Independent 
Chi-squared test Categorical n/a ≥2 Independent 
Wilcoxon signed rank sum test Continuous not normal 2 Paired 
McNemar’s test Categorical n/a 2 Dependent 
Marginal homogeneity test Categorical n/a >2 Dependent 
Linear regression Continuous Gaussian 2 Independent 
Logistic regression Binary Binomial 2 Independent 
Ordinal logistic regression Ordinal Multinomial ≥2 Independent 
Poisson regression Counts Poisson >2 Independent 
Conditional linear regression Continuous Gaussian ≥2 Dependent 
Conditional logistic regression Binary Binomial 2 Dependent 
Conditional ordinal logistic 
regression Ordinal Multinomial ≥2 Dependent 
Conditional Poisson regression Counts Poisson >2 Dependent 
 
  
Table A3: Formulae for Standardised Mean Difference 
Covariate type Formula 
Continuous 
𝑆𝑆𝑆𝑆𝑆𝑆 = (𝑥𝑥𝑡𝑡���− 𝑥𝑥𝑟𝑟 ����)
�𝑠𝑠𝑡𝑡
2+ 𝑠𝑠𝑟𝑟2
2
 , 
where 𝑥𝑥𝑡𝑡�  , 𝑥𝑥𝑟𝑟 ���� denote the sample means and 𝑠𝑠𝑡𝑡 ,𝑠𝑠𝑟𝑟 the standard 
deviations 
Binary 
𝑆𝑆𝑆𝑆𝑆𝑆 = (𝑝𝑝𝑡𝑡 �− 𝑝𝑝𝑟𝑟�)
�𝑝𝑝�𝑡𝑡(1−𝑝𝑝�𝑡𝑡)+𝑝𝑝�𝑟𝑟(1−𝑝𝑝�𝑟𝑟)
2
 , 
where 𝑝𝑝𝑡𝑡�   ,𝑝𝑝𝑟𝑟�    denote the proportion of patients in each category 
Categorical (>2 
categories) 
𝑆𝑆𝑆𝑆𝑆𝑆 = �(𝑇𝑇 − 𝐶𝐶)′𝑆𝑆−1(𝑇𝑇 − 𝐶𝐶) 
where 𝑆𝑆 is a (𝑘𝑘 − 1) × (𝑘𝑘 − 1) covariance matrix: 
𝑆𝑆 = [𝑆𝑆𝑘𝑘𝑘𝑘] = �?̂?𝑝1𝑘𝑘  (1 − ?̂?𝑝1𝑘𝑘) +  ?̂?𝑝2𝑘𝑘 (1−𝑝𝑝�2𝑘𝑘)   2  ,𝑘𝑘 = 𝑙𝑙?̂?𝑝1𝑘𝑘 ?̂?𝑝1𝑘𝑘 + ?̂?𝑝2𝑘𝑘 ?̂?𝑝2𝑘𝑘 2 , 𝑘𝑘 ≠ 𝑙𝑙  
, 𝑇𝑇 = (?̂?𝑝12 , … , ?̂?𝑝1𝑘𝑘   )′ , 𝐶𝐶 = (?̂?𝑝22 , … , ?̂?𝑝2𝑘𝑘   )′  and ?̂?𝑝𝑗𝑗𝑘𝑘 =
𝑃𝑃 (𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐 𝑘𝑘|𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑐𝑡𝑡𝑐𝑐𝑡𝑡𝑐𝑐 𝑐𝑐𝑐𝑐𝑡𝑡 𝑗𝑗) , 𝑗𝑗 = 1,2  ,𝑘𝑘 = 2,3, …  , 𝑘𝑘 
 
  
Table A4: Formulae for Relative Change in Co-efficient 
Outcome type Regression type Formula 
Continuous Linear 𝑅𝑅𝐶𝐶𝐶𝐶 = 𝑐𝑐𝑎𝑎𝑠𝑠 ��𝛽𝛽𝑐𝑐𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐 −    𝛽𝛽𝑎𝑎𝑐𝑐𝑗𝑗𝑐𝑐𝑎𝑎𝑡𝑡𝑐𝑐𝑐𝑐�
𝛽𝛽𝑐𝑐𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐
� 
Binary Logistic 
𝑅𝑅𝐶𝐶𝐶𝐶 = 𝑐𝑐𝑎𝑎𝑠𝑠(1 − 𝑐𝑐� 𝛽𝛽𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑠𝑠𝑡𝑡𝑎𝑎𝑎𝑎−𝛽𝛽𝑐𝑐𝑟𝑟𝑎𝑎𝑎𝑎𝑎𝑎�) Time-to-event Cox-Proportional Hazard 
Count Poisson 
Note: where 𝛽𝛽𝑐𝑐𝑟𝑟𝑐𝑐𝑐𝑐𝑐𝑐 is the co-efficient of exposure in the crude model and 𝛽𝛽𝑎𝑎𝑐𝑐𝑗𝑗𝑐𝑐𝑎𝑎𝑡𝑡𝑐𝑐𝑐𝑐  is the co-efficient of exposure 
after adding the covariate in the model. 
 
  
Table A5: Detailed results outcome 1 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
Age at IPD 
(years) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.015 
Mean (SD) 57.9 (15.6) 59.7 (14.7) 58.6 (15.2) 
Median (IQR) 60 (48, 71) 62 (52, 72) 61 (50, 71) 
Min, Max (12, 80) (13, 80) (12, 80) 
Age at IPD 
(years) 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.106 
12-18, n (%) 7 (0.6) 6 (0.7) 13 (0.7) 
19-35, n (%) 118 (10.2) 67 (8.0) 185 (9.3) 
36-65, n (%) 582 (50.5) 402 (47.9) 984 (49.4) 
66-80, n (%) 445 (38.6) 364 (43.4) 809 (40.6) 
Gender 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.309 Male, n (%) 617 (53.6) 430 (51.3) 1047 (52.6) 
Female, n (%) 535 (46.4) 409 (48.7) 944 (47.4) 
Insurance 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.031 
Medical insurance, n (%) 1006 (87.3) 698 (83.2) 1704 (85.6) 
Medical aid, n (%) 144 (12.5) 138 (16.4) 282 (14.2) 
Veterans cover, n (%) 2 (0.2) 3 (0.4) 5 (0.3) 
COMORBIDITIES 
 Measure Persistent Cohort 
Non-Persistent 
Cohort Total Cohort p-value* 
COPD 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.865 No, n (%) 420 (36.5) 309 (36.8) 729 (36.6) 
Yes, n (%) 732 (63.5) 530 (63.2) 1262 (63.4) 
COPD (ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.288 No, n (%) 258 (22.4) 205 (24.4) 463 (23.3) 
Yes, n (%) 894 (77.6) 634 (75.6) 1528 (76.7) 
Oral thrush 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.474 No, n (%) 1142 (99.1) 829 (98.8) 1971 (99.0) 
Yes, n (%) 10 (0.9) 10 (1.2) 20 (1.0) 
Oral thrush (ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.364 No, n (%) 1136 (98.6) 823 (98.1) 1959 (98.4) 
Yes, n (%) 16 (1.4) 16 (1.9) 32 (1.6) 
Comorbid eczema N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 0.840 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
No, n (%) 1102 (95.7) 801 (95.5) 1903 (95.6) 
Yes, n (%) 50 (4.3) 38 (4.5) 88 (4.4) 
Comorbid eczema 
(ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.992 No, n (%) 1031 (89.5) 751 (89.5) 1782 (89.5) 
Yes, n (%) 121 (10.5) 88 (10.5) 209 (10.5) 
Comorbid GERD 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.024 No, n (%) 806 (70.0) 547 (65.2) 1353 (68.0) 
Yes, n (%) 346 (30.0) 292 (34.8) 638 (32.0) 
Comorbid GERD 
(ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.050 No, n (%) 606 (52.6) 404 (48.2) 1010 (50.7) 
Yes, n (%) 546 (47.4) 435 (51.8) 981 (49.3) 
Ischaemic heart 
disease 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.540 No, n (%) 1054 (91.5) 761 (90.7) 1815 (91.2) 
Yes, n (%) 98 (8.5) 78 (9.3) 176 (8.8) 
Ischaemic heart 
disease (ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.982 No, n (%) 1000 (86.8) 728 (86.8) 1728 (86.8) 
Yes, n (%) 152 (13.2) 111 (13.2) 263 (13.2) 
Influenza 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.081 No, n (%) 1128 (97.9) 830 (98.9) 1958 (98.3) 
Yes, n (%) 24 (2.1) 9 (1.1) 33 (1.7) 
Influenza (ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.712 No, n (%) 1110 (96.4) 811 (96.7) 1921 (96.5) 
Yes, n (%) 42 (3.6) 28 (3.3) 70 (3.5) 
Other chronic lung 
diseases 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.990 No, n (%) 680 (59.0) 495 (59.0) 1175 (59.0) 
Yes, n (%) 472 (41.0) 344 (41.0) 816 (41.0) 
Other chronic lung 
diseases (ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.149 No, n (%) 445 (38.6) 351 (41.8) 796 (40.0) 
Yes, n (%) 707 (61.4) 488 (58.2) 1195 (60.0) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 0.817 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
Comorbid nasal 
polyps 
No, n (%) 1129 (98.0) 821 (97.9) 1950 (97.9) 
Yes, n (%) 23 (2.0) 18 (2.1) 41 (2.1) 
Comorbid nasal 
polyps (ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.582 No, n (%) 1098 (95.3) 804 (95.8) 1902 (95.5) 
Yes, n (%) 54 (4.7) 35 (4.2) 89 (4.5) 
Pneumonia 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.129 No, n (%) 1043 (90.5) 742 (88.4) 1785 (89.7) 
Yes, n (%) 109 (9.5) 97 (11.6) 206 (10.3) 
Pneumonia (ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.737 No, n (%) 950 (82.5) 687 (81.9) 1637 (82.2) 
Yes, n (%) 202 (17.5) 152 (18.1) 354 (17.8) 
Comorbid rhinitis 
(active) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.179 No, n (%) 411 (35.7) 324 (38.6) 735 (36.9) 
Yes, n (%) 741 (64.3) 515 (61.4) 1256 (63.1) 
Comorbid rhinitis 
(ever) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.874 No, n (%) 226 (19.6) 167 (19.9) 393 (19.7) 
Yes, n (%) 926 (80.4) 672 (80.1) 1598 (80.3) 
Charlson 
Comorbidity Index 
(CCI) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.058 
Mean (SD) 1.4 (0.9) 1.5 (0.9) 1.4 (0.9) 
Median (IQR) 1 (1, 1) 1 (1, 1) 1 (1, 1) 
Min, Max (0, 7) (0, 6) (0, 7) 
Charlson 
Comorbidity Index 
(CCI) (categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.152 
0-1, n (%) 920 (79.9) 641 (76.4) 1561 (78.4) 
2-5, n (%) 228 (19.8) 193 (23.0) 421 (21.1) 
6-10 n (%) 4 (0.3) 5 (0.6) 9 (0.5) 
DISEASE SEVERITY & HEALTHCARE UTILIZATION 
 Measure Persistent Cohort 
Non-Persistent 
Cohort Total Cohort p-value 
All inpatient 
admissions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.022 
Mean (SD) 0.9 (1.9) 1.1 (2.3) 1.0 (2.1) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
Median (IQR) 0 (0, 1) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 24) (0, 18) (0, 24) 
All inpatient 
admissions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.038 
0, n (%) 728 (63.2) 489 (58.3) 1217 (61.1) 
1, n (%) 210 (18.2) 175 (20.9) 385 (19.3) 
2, n (%) 101 (8.8) 72 (8.6) 173 (8.7) 
3, n (%) 47 (4.1) 30 (3.6) 77 (3.9) 
≥4, n (%) 66 (5.7) 73 (8.7) 139 (7.0) 
All inpatient 
admissions days 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.015 
Mean (SD) 9.0 (26.7) 12.0 (34.7) 10.3 (30.4) 
Median (IQR) 0 (0, 7) 0 (0, 9) 0 (0, 8) 
Min, Max (0, 318) (0, 388) (0, 388) 
All inpatient 
admissions days 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
Data 
visualisatio
n only 
0, n (%) 728 (63.2) 489 (58.3) 1217 (61.1) 
1-3, n (%) 70 (6.1) 50 (6.0) 120 (6.0) 
4-6, n (%) 58 (5.0) 51 (6.1) 109 (5.5) 
7-13, n (%) 102 (8.9) 84 (10.0) 186 (9.3) 
≥14, n (%) 194 (16.8) 165 (19.7) 359 (18.0) 
LRTI-related 
inpatient 
admissions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.003 
Mean (SD) 0.3 (0.7) 0.4 (0.9) 0.3 (0.8) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 7) (0, 10) (0, 10) 
LRTI-related 
inpatient 
admissions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.045 
0, n (%) 933 (81.0) 634 (75.6) 1567 (78.7) 
1, n (%) 160 (13.9) 143 (17.0) 303 (15.2) 
2, n (%) 39 (3.4) 39 (4.6) 78 (3.9) 
3, n (%) 10 (0.9) 9 (1.1) 19 (1.0) 
≥4, n (%) 10 (0.9) 14 (1.7) 24 (1.2) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.003 
Mean (SD) 3.5 (13.6) 4.5 (14.4) 3.9 (14.0) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
LRTI-related 
inpatient 
admissions days 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 259) (0, 156) (0, 259) 
LRTI-related 
inpatient 
admissions days 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
 Data 
visualisatio
n only 
0, n (%) 933 (81.0) 634 (75.6) 1567 (78.7) 
1-3, n (%) 27 (2.3) 21 (2.5) 48 (2.4) 
4-6, n (%) 37 (3.2) 37 (4.4) 74 (3.7) 
7-13, n (%) 68 (5.9) 63 (7.5) 131 (6.6) 
≥14, n (%) 87 (7.6) 84 (10.0) 171 (8.6) 
Asthma-related 
inpatient 
admissions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.025 
Mean (SD) 0.2 (0.8) 0.3 (0.9) 0.3 (0.9) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 12) (0, 12) (0, 12) 
Asthma-related 
inpatient 
admissions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.255 
0, n (%) 978 (84.9) 680 (81.0) 1658 (83.3) 
1, n (%) 118 (10.2) 110 (13.1) 228 (11.5) 
2, n (%) 35 (3.0) 31 (3.7) 66 (3.3) 
3, n (%) 8 (0.7) 6 (0.7) 14 (0.7) 
≥4, n (%) 13 (1.1) 12 (1.4) 25 (1.3) 
Asthma-related 
inpatient 
admissions days 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.026 
Mean (SD) 2.6 (11.6) 3.1 (12.0) 2.8 (11.8) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 259) (0, 156) (0, 259) 
Asthma-related 
inpatient 
admissions days 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
Data 
visualisatio
n only 
0, n (%) 978 (84.9) 680 (81.0) 1658 (83.3) 
1-3, n (%) 22 (1.9) 22 (2.6) 44 (2.2) 
4-6, n (%) 33 (2.9) 29 (3.5) 62 (3.1) 
7-13, n (%) 54 (4.7) 52 (6.2) 106 (5.3) 
≥14, n (%) 65 (5.6) 56 (6.7) 121 (6.1) 
Asthma 
exacerbation-
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
Mean (SD) 0.1 (0.4) 0.2 (0.6) 0.1 (0.5) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
related inpatient 
admissions 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 5) (0, 7) (0, 7) 
Asthma 
exacerbation-
related inpatient 
admissions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.011 
0, n (%) 1095 (95.1) 765 (91.2) 1860 (93.4) 
1, n (%) 38 (3.3) 44 (5.2) 82 (4.1) 
2, n (%) 12 (1.0) 18 (2.1) 30 (1.5) 
3, n (%) 4 (0.3) 5 (0.6) 9 (0.5) 
≥4, n (%) 3 (0.3) 7 (0.8) 10 (0.5) 
Asthma 
exacerbation-
related inpatient 
admissions days 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
Mean (SD) 0.7 (4.6) 1.7 (9.2) 1.1 (7.0) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 78) (0, 156) (0, 156) 
Asthma 
exacerbation-
related inpatient 
admissions days 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
Data 
visualisatio
n only 
0, n (%) 1095 (95.1) 765 (91.2) 1860 (93.4) 
1-3, n (%) 9 (0.8) 11 (1.3) 20 (1.0) 
4-6, n (%) 14 (1.2) 11 (1.3) 25 (1.3) 
7-13, n (%) 16 (1.4) 22 (2.6) 38 (1.9) 
≥14, n (%) 18 (1.6) 30 (3.6) 48 (2.4) 
All outpatient 
attendances 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
Mean (SD) 33.0 (26.5) 37.1 (27.3) 34.8 (26.9) 
Median (IQR) 26 (16, 42) 30 (18, 48) 27 (17, 44) 
Min, Max (2, 225) (3, 220) (2, 225) 
All outpatient 
attendances 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
1-12, n (%) 181 (15.7) 102 (12.2) 283 (14.2) 
13-24, n (%) 366 (31.8) 229 (27.3) 595 (29.9) 
25-36, n (%) 244 (21.2) 174 (20.7) 418 (21.0) 
37-48, n (%) 154 (13.4) 125 (14.9) 279 (14.0) 
≥48, n (%) 207 (18.0) 209 (24.9) 416 (20.9) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
Mean (SD) 28.1 (22.6) 31.5 (23.7) 29.5 (23.1) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
LRTI-related 
outpatient 
attendances 
Median (IQR) 22 (14, 35) 25 (15, 40) 23 (14, 37) 
Min, Max (2, 216) (3, 207) (2, 216) 
LRTI-related 
outpatient 
attendances 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
1-12, n (%) 236 (20.5) 135 (16.1) 371 (18.6) 
13-24, n (%) 416 (36.1) 271 (32.3) 687 (34.5) 
25-36, n (%) 234 (20.3) 175 (20.9) 409 (20.5) 
37-48, n (%) 127 (11.0) 114 (13.6) 241 (12.1) 
≥48, n (%) 139 (12.1) 144 (17.2) 283 (14.2) 
Asthma-related 
outpatient 
attendances 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
Mean (SD) 7.5 (8.6) 8.9 (9.8) 8.1 (9.1) 
Median (IQR) 6 (3, 9) 7 (3, 11) 6 (3, 10) 
Min, Max (0, 105) (0, 135) (0, 135) 
Asthma-related 
outpatient 
attendances 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.005 
0, n (%) 87 (7.6) 49 (5.8) 136 (6.8) 
1-3, n (%) 263 (22.8) 165 (19.7) 428 (21.5) 
4-6, n (%) 306 (26.6) 200 (23.8) 506 (25.4) 
7-9, n (%) 214 (18.6) 153 (18.2) 367 (18.4) 
10-12, n (%) 107 (9.3) 101 (12.0) 208 (10.4) 
≥13, n (%) 175 (15.2) 171 (20.4) 346 (17.4) 
All emergency 
attendances 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.051 
Mean (SD) 0.4 (1.0) 0.5 (1.0) 0.4 (1.0) 
Median (IQR) 0 (0, 0) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 15) (0, 9) (0, 15) 
All emergency 
attendances 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.032 
0, n (%) 866 (75.2) 604 (72.0) 1470 (73.8) 
1, n (%) 195 (16.9) 136 (16.2) 331 (16.6) 
2, n (%) 56 (4.9) 53 (6.3) 109 (5.5) 
3, n (%) 15 (1.3) 24 (2.9) 39 (2.0) 
≥4, n (%) 20 (1.7) 22 (2.6) 42 (2.1) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 0.051 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
LRTI-related 
emergency 
attendances 
Mean (SD) 0.4 (1.0) 0.5 (1.0) 0.4 (1.0) 
Median (IQR) 0 (0, 0) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 15) (0, 9) (0, 15) 
LRTI-related 
emergency 
attendances 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.027 
0, n (%) 866 (75.2) 604 (72.0) 1470 (73.8) 
1, n (%) 202 (17.5) 141 (16.8) 343 (17.2) 
2, n (%) 50 (4.3) 51 (6.1) 101 (5.1) 
3, n (%) 17 (1.5) 27 (3.2) 44 (2.2) 
≥4, n (%) 17 (1.5) 16 (1.9) 33 (1.7) 
Asthma-related 
emergency 
attendances 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.397 
Mean (SD) 0.1 (0.5) 0.1 (0.5) 0.1 (0.5) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 7) (0, 5) (0, 7) 
Asthma-related 
emergency 
attendances 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.419 
0, n (%) 1049 (91.1) 755 (90.0) 1804 (90.6) 
1, n (%) 80 (6.9) 61 (7.3) 141 (7.1) 
2, n (%) 15 (1.3) 13 (1.5) 28 (1.4) 
3, n (%) 6 (0.5) 4 (0.5) 10 (0.5) 
≥4, n (%) 2 (0.2) 6 (0.7) 8 (0.4) 
Antibiotics 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.156 
Mean (SD) 1.1 (1.9) 1.3 (2.4) 1.2 (2.1) 
Median (IQR) 0 (0, 1) 0 (0, 2) 0 (0, 2) 
Min, Max (0, 15) (0, 24) (0, 24) 
Antibiotics 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.424 
0, n (%) 645 (56.0) 445 (53.0) 1090 (54.7) 
1-3, n (%) 404 (35.1) 313 (37.3) 717 (36.0) 
4-6, n (%) 69 (6.0) 51 (6.1) 120 (6.0) 
7-9, n (%) 25 (2.2) 16 (1.9) 41 (2.1) 
10-12, n (%) 5 (0.4) 8 (1.0) 13 (0.7) 
≥13, n (%) 4 (0.3) 6 (0.7) 10 (0.5) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
Acute OCS 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.444 
Mean (SD) 1.2 (2.7) 1.2 (2.3) 1.2 (2.5) 
Median (IQR) 0 (0, 1) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 36) (0, 26) (0, 36) 
Acute OCS 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.826 
0, n (%) 686 (59.5) 486 (57.9) 1172 (58.9) 
1, n (%) 205 (17.8) 146 (17.4) 351 (17.6) 
2, n (%) 88 (7.6) 71 (8.5) 159 (8.0) 
3, n (%) 64 (5.6) 55 (6.6) 119 (6.0) 
≥4, n (%) 109 (9.5) 81 (9.7) 190 (9.5) 
Non-acute OCS 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.458 
Mean (SD) 0.7 (1.2) 0.7 (1.2) 0.7 (1.2) 
Median (IQR) 0 (0, 1) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 9) (0, 11) (0, 11) 
Non-acute OCS 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.061 
0, n (%) 742 (64.4) 519 (61.9) 1261 (63.3) 
1, n (%) 191 (16.6) 167 (19.9) 358 (18.0) 
2, n (%) 108 (9.4) 86 (10.3) 194 (9.7) 
3, n (%) 68 (5.9) 31 (3.7) 99 (5.0) 
≥4, n (%) 43 (3.7) 36 (4.3) 79 (4.0) 
Severe 
exacerbations 
(ATS/ERS) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.019 
Mean (SD) 0.7 (0.8) 0.8 (0.9) 0.7 (0.9) 
Median (IQR) 1 (0, 1) 1 (0, 1) 1 (0, 1) 
Min, Max (0, 9) (0, 7) (0, 9) 
Severe 
exacerbations 
(ATS/ERS) 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.007 
0, n (%) 531 (46.1) 353 (42.1) 884 (44.4) 
1, n (%) 525 (45.6) 390 (46.5) 915 (46.0) 
2, n (%) 69 (6.0) 51 (6.1) 120 (6.0) 
3, n (%) 15 (1.3) 25 (3.0) 40 (2.0) 
≥4, n (%) 12 (1.0) 20 (2.4) 32 (1.6) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
Acute respiratory 
event 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.022 
Mean (SD) 1.2 (1.4) 1.4 (2.0) 1.3 (1.7) 
Median (IQR) 1 (0, 1) 1 (0, 2) 1 (0, 2) 
Min, Max (0, 12) (0, 24) (0, 24) 
Acute respiratory 
event (categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.070 
0, n (%) 375 (32.6) 245 (29.2) 620 (31.1) 
1, n (%) 502 (43.6) 363 (43.3) 865 (43.4) 
2, n (%) 139 (12.1) 96 (11.4) 235 (11.8) 
3, n (%) 58 (5.0) 61 (7.3) 119 (6.0) 
≥4, n (%) 78 (6.8) 74 (8.8) 152 (7.6) 
MEDICATION USE 
 Measure Persistent Cohort 
Non-Persistent 
Cohort Total Cohort p-value 
FDC ICS/LABA 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
Mean (SD) 4.5 (2.7) 5.3 (2.8) 4.8 (2.8) 
Median (IQR) 4 (2, 6) 5 (3, 7) 4 (3, 6) 
Min, Max (2, 21) (2, 14) (2, 21) 
FDC ICS/LABA 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 2-3, n (%) 529 (45.9) 282 (33.6) 811 (40.7) 
≥4, n (%) 623 (54.1) 557 (66.4) 1180 (59.3) 
ICS only 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.688 
Mean (SD) 0.5 (1.5) 0.7 (2.6) 0.6 (2.1) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 24) (0, 63) (0, 63) 
ICS only 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.877 No, n (%) 874 (75.9) 634 (75.6) 1508 (75.7) 
Yes, n (%) 278 (24.1) 205 (24.4) 483 (24.3) 
ICS only 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.170 0, n (%) 874 (75.9) 634 (75.6) 1508 (75.7) 
1, n (%) 148 (12.8) 100 (11.9) 248 (12.5) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
2, n (%) 62 (5.4) 35 (4.2) 97 (4.9) 
3, n (%) 29 (2.5) 26 (3.1) 55 (2.8) 
≥4, n (%) 39 (3.4) 44 (5.2) 83 (4.2) 
ICS average daily 
dose 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
Mean (SD) 373.7 (271.9) 406.3 (268.1) 387.5 (270.7) 
Median (IQR) 303.1 (179.8, 467.5) 
328.8 (205.5, 
534.2) 
314.0 (205.5, 
493.2) 
Min, Max (65.8, 3565.2) (49.3, 2381.6) (49.3, 3565.2) 
ICS average daily 
dose (categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.005 
>0-250, n (%) 475 (41.2) 297 (35.4) 772 (38.8) 
>250-500, n (%) 430 (37.3) 315 (37.5) 745 (37.4) 
>500, n (%) 247 (21.4) 227 (27.1) 474 (23.8) 
IV/IM CS 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.002 
Mean (SD) 2.3 (4.5) 3.0 (6.1) 2.6 (5.2) 
Median (IQR) 1 (0, 3) 1 (0, 3) 1 (0, 3) 
Min, Max (0, 51) (0, 80) (0, 80) 
IV/IM CS 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.018 No, n (%) 485 (42.1) 309 (36.8) 794 (39.9) 
Yes, n (%) 667 (57.9) 530 (63.2) 1197 (60.1) 
IV/IM CS 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.102 
0, n (%) 485 (42.1) 309 (36.8) 794 (39.9) 
1-3, n (%) 433 (37.6) 323 (38.5) 756 (38.0) 
4-8, n (%) 162 (14.1) 141 (16.8) 303 (15.2) 
9-13, n (%) 34 (3.0) 32 (3.8) 66 (3.3) 
≥13, n (%) 38 (3.3) 34 (4.1) 72 (3.6) 
SABA 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
Mean (SD) 3.3 (6.2) 4.1 (6.7) 3.6 (6.4) 
Median (IQR) 1 (0, 4) 2 (0, 5) 1 (0, 4) 
Min, Max (0, 64) (0, 68) (0, 68) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 0.003 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
SABA 
prescriptions 
(yes/no) 
No, n (%) 426 (37.0) 257 (30.6) 683 (34.3) 
Yes, n (%) 726 (63.0) 582 (69.4) 1308 (65.7) 
SABA 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.001 
0, n (%) 426 (37.0) 257 (30.6) 683 (34.3) 
1-3, n (%) 436 (37.8) 299 (35.6) 735 (36.9) 
4-6, n (%) 118 (10.2) 123 (14.7) 241 (12.1) 
7-9, n (%) 67 (5.8) 59 (7.0) 126 (6.3) 
10-12, n (%) 38 (3.3) 30 (3.6) 68 (3.4) 
≥13, n (%) 67 (5.8) 71 (8.5) 138 (6.9) 
SABA inhaler 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.011 
Mean (SD) 1.7 (3.8) 2.1 (4.0) 1.8 (3.9) 
Median (IQR) 0 (0, 1) 0 (0, 2) 0 (0, 2) 
Min, Max (0, 64) (0, 32) (0, 64) 
SABA inhaler 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.055 No, n (%) 650 (56.4) 437 (52.1) 1087 (54.6) 
Yes, n (%) 502 (43.6) 402 (47.9) 904 (45.4) 
SABA inhaler 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.166 
0, n (%) 650 (56.4) 437 (52.1) 1087 (54.6) 
1-3, n (%) 345 (29.9) 254 (30.3) 599 (30.1) 
4-6, n (%) 71 (6.2) 63 (7.5) 134 (6.7) 
7-9, n (%) 37 (3.2) 33 (3.9) 70 (3.5) 
10-12, n (%) 23 (2.0) 28 (3.3) 51 (2.6) 
≥13, n (%) 26 (2.3) 24 (2.9) 50 (2.5) 
SABA inhaler 
average daily dose 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.011 
Mean (SD) 127.4 (362.9) 157.3 (358.3) 140.0 (361.2) 
Median (IQR) 0 (0, 110) 0 (0, 110) 0 (0, 110) 
Min, Max (0, 6630) (0, 4384) (0, 6630) 
SABA inhaler 
average daily dose 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.060 0, n (%) 650 (56.4) 437 (52.1) 1087 (54.6) 
>0-200, n (%) 327 (28.4) 235 (28.0) 562 (28.2) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
>200-400, n (%) 74 (6.4) 64 (7.6) 138 (6.9) 
>400-800, n (%) 57 (4.9) 63 (7.5) 120 (6.0) 
≥800, n (%) 44 (3.8) 40 (4.8) 84 (4.2) 
SABA nebuliser 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.019 
Mean (SD) 1.1 (3.3) 1.3 (3.5) 1.2 (3.4) 
Median (IQR) 0 (0, 1) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 50) (0, 51) (0, 51) 
SABA nebuliser 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.039 No, n (%) 743 (64.5) 503 (60.0) 1246 (62.6) 
Yes, n (%) 409 (35.5) 336 (40.0) 745 (37.4) 
SABA nebuliser 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.063 
0, n (%) 743 (64.5) 503 (60.0) 1246 (62.6) 
1-3, n (%) 325 (28.2) 249 (29.7) 574 (28.8) 
4-6, n (%) 50 (4.3) 57 (6.8) 107 (5.4) 
7-9, n (%) 12 (1.0) 12 (1.4) 24 (1.2) 
10-12, n (%) 7 (0.6) 10 (1.2) 17 (0.9) 
≥13, n (%) 15 (1.3) 8 (1.0) 23 (1.2) 
SABA oral 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.035 
Mean (SD) 0.5 (2.3) 0.7 (3.0) 0.6 (2.6) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 45) (0, 51) (0, 51) 
SABA oral 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.039 No, n (%) 1003 (87.1) 703 (83.8) 1706 (85.7) 
Yes, n (%) 149 (12.9) 136 (16.2) 285 (14.3) 
SABA oral 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.088 
0, n (%) 1003 (87.1) 703 (83.8) 1706 (85.7) 
1-3, n (%) 105 (9.1) 89 (10.6) 194 (9.7) 
4-6, n (%) 19 (1.6) 20 (2.4) 39 (2.0) 
7-9, n (%) 12 (1.0) 9 (1.1) 21 (1.1) 
10-12, n (%) 7 (0.6) 4 (0.5) 11 (0.6) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
≥13, n (%) 6 (0.5) 14 (1.7) 20 (1.0) 
FDC SABA/SAMA 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.394 
Mean (SD) 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 1) (0, 0) (0, 1) 
SAMA 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.044 
Mean (SD) 0.6 (2.6) 0.5 (2.2) 0.6 (2.5) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 50) (0, 51) (0, 51) 
SAMA 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.041 No, n (%) 915 (79.4) 634 (75.6) 1549 (77.8) 
Yes, n (%) 237 (20.6) 205 (24.4) 442 (22.2) 
SAMA 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.169 
0, n (%) 915 (79.4) 634 (75.6) 1549 (77.8) 
1, n (%) 140 (12.2) 125 (14.9) 265 (13.3) 
2, n (%) 48 (4.2) 31 (3.7) 79 (4.0) 
3, n (%) 17 (1.5) 17 (2.0) 34 (1.7) 
≥4, n (%) 32 (2.8) 32 (3.8) 64 (3.2) 
LAMA 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.219 
Mean (SD) 1.3 (2.8) 1.5 (3.1) 1.4 (2.9) 
Median (IQR) 0 (0, 1) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 14) (0, 15) (0, 15) 
LAMA 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.274 No, n (%) 864 (75.0) 611 (72.8) 1475 (74.1) 
Yes, n (%) 288 (25.0) 228 (27.2) 516 (25.9) 
LAMA 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
<0.001 
0, n (%) 864 (75.0) 611 (72.8) 1475 (74.1) 
1-2, n (%) 62 (5.4) 63 (7.5) 125 (6.3) 
3-4, n (%) 90 (7.8) 31 (3.7) 121 (6.1) 
≥5, n (%) 136 (11.8) 134 (16.0) 270 (13.6) 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
FDC LABA/LAMA 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.393 No, n (%) 1151 (99.9) 839 (100.0) 1990 (99.9) 
Yes, n (%) 1 (0.1) 0 (0.0) 1 (0.1) 
LABA inhaler 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.785 
Mean (SD) 0.1 (0.5) 0.1 (0.6) 0.1 (0.5) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 10) (0, 12) (0, 12) 
LABA inhaler 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.782 No, n (%) 1128 (97.9) 823 (98.1) 1951 (98.0) 
Yes, n (%) 24 (2.1) 16 (1.9) 40 (2.0) 
LABA inhaler 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.904 
0, n (%) 1128 (97.9) 823 (98.1) 1951 (98.0) 
1, n (%) 14 (1.2) 8 (1.0) 22 (1.1) 
2, n (%) 2 (0.2) 3 (0.4) 5 (0.3) 
3, n (%) 3 (0.3) 2 (0.2) 5 (0.3) 
≥4, n (%) 5 (0.4) 3 (0.4) 8 (0.4) 
LABA oral 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.136 
Mean (SD) 1.4 (3.3) 1.7 (4.4) 1.5 (3.8) 
Median (IQR) 0 (0, 1) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 34) (0, 49) (0, 49) 
LABA oral 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.149 No, n (%) 804 (69.8) 560 (66.7) 1364 (68.5) 
Yes, n (%) 348 (30.2) 279 (33.3) 627 (31.5) 
LABA oral 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.563 
0, n (%) 804 (69.8) 560 (66.7) 1364 (68.5) 
1-3, n (%) 199 (17.3) 151 (18.0) 350 (17.6) 
4-6, n (%) 67 (5.8) 56 (6.7) 123 (6.2) 
7-11, n (%) 51 (4.4) 42 (5.0) 93 (4.7) 
≥12, n (%) 31 (2.7) 30 (3.6) 61 (3.1) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 0.660 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
LABA patch 
prescriptions 
Mean (SD) 0.3 (1.5) 0.4 (1.9) 0.3 (1.7) 
Median (IQR) 0 (0, 0) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 19) (0, 31) (0, 31) 
LABA patch 
prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.650 No, n (%) 1041 (90.4) 753 (89.7) 1794 (90.1) 
Yes, n (%) 111 (9.6) 86 (10.3) 197 (9.9) 
LABA patch 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.484 
0, n (%) 1041 (90.4) 753 (89.7) 1794 (90.1) 
1-2, n (%) 69 (6.0) 51 (6.1) 120 (6.0) 
3-4, n (%) 16 (1.4) 17 (2.0) 33 (1.7) 
5-6, n (%) 6 (0.5) 8 (1.0) 14 (0.7) 
≥7, n (%) 20 (1.7) 10 (1.2) 30 (1.5) 
LTRA prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.378 
Mean (SD) 5.0 (5.5) 5.2 (7.2) 5.1 (6.3) 
Median (IQR) 4 (1, 7) 4 (0, 7) 4 (1, 7) 
Min, Max (0, 77) (0, 123) (0, 123) 
LTRA prescriptions 
(yes/no) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.331 No, n (%) 268 (23.3) 211 (25.1) 479 (24.1) 
Yes, n (%) 884 (76.7) 628 (74.9) 1512 (75.9) 
LTRA prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.176 
0, n (%) 268 (23.3) 211 (25.1) 479 (24.1) 
1-3, n (%) 257 (22.3) 206 (24.6) 463 (23.3) 
4-6, n (%) 279 (24.2) 165 (19.7) 444 (22.3) 
7-11, n (%) 212 (18.4) 155 (18.5) 367 (18.4) 
≥12, n (%) 136 (11.8) 102 (12.2) 238 (12.0) 
Theophylline or 
other 
methylxanthine 
prescriptions 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.001 
Mean (SD) 4.6 (6.4) 5.9 (8.1) 5.1 (7.2) 
Median (IQR) 2 (0, 7) 3 (0, 9) 3 (0, 8) 
Min, Max (0, 76) (0, 73) (0, 76) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 0.061 
 Measure Persistent 
Cohort 
Non-Persistent 
Cohort Total Cohort 
p-value* 
Theophylline or 
other 
methylxanthine 
prescriptions 
(yes/no) 
No, n (%) 372 (32.3) 238 (28.4) 610 (30.6) 
Yes, n (%) 780 (67.7) 601 (71.6) 1381 (69.4) 
Theophylline or 
other 
methylxanthine 
prescriptions 
(categorised) 
N (% not missing) 1152 (100.0) 839 (100.0) 1991 (100.0) 
0.003 
0, n (%) 372 (32.3) 238 (28.4) 610 (30.6) 
1-3, n (%) 274 (23.8) 188 (22.4) 462 (23.2) 
4-6, n (%) 198 (17.2) 131 (15.6) 329 (16.5) 
7-11, n (%) 174 (15.1) 135 (16.1) 309 (15.5) 
≥12, n (%) 134 (11.6) 147 (17.5) 281 (14.1) 
* Mann-Whitney test for continuous variables and Chi-squared test for categorical variables 
  
Table A6: Baseline characteristics outcome 2 
 Measure Patients changing from DPI to pMDI 
Age at IPD (years) 
N (% not missing) 667 (100.0) 
Mean (SD) 58.1 (15.1) 
Median (IQR) 60 (49, 70) 
Min, Max (12, 80) 
Age at IPD (years) (categorised) 
N (% not missing) 667(100) 
12-18, n (%) 2 (0.3) 
19-35, n (%) 63 (9.4) 
36-65, n (%) 347 (52.0) 
66-80, n (%) 255 (38.2) 
Gender 
N (% not missing) 667(100) 
Male, n (%) 366 (54.9) 
Female, n (%) 301 (45.1) 
Insurance 
N (% not missing) 667(100) 
Medical insurance, n (%) 586 (87.9) 
Medical aid, n (%) 79 (11.8) 
Veterans cover, n (%) 2 (0.3) 
COMORBIDITIES 
 Measure Patients changing from DPI to pMDI 
COPD 
N (% not missing) 667(100) 
No, n (%) 247 (37.0) 
Yes, n (%) 420 (63.0) 
COPD (ever) 
N (% not missing) 667(100) 
No, n (%) 170 (25.5) 
Yes, n (%) 497 (74.5) 
Oral thrush 
N (% not missing) 667(100) 
No, n (%) 659 (98.8) 
Yes, n (%) 8 (1.2) 
Oral thrush (ever) 
N (% not missing) 667(100) 
No, n (%) 653 (97.9) 
 Measure Patients changing from DPI to pMDI 
Yes, n (%) 14 (2.1) 
Comorbid eczema 
N (% not missing) 667(100) 
No, n (%) 638 (95.7) 
Yes, n (%) 29 (4.3) 
Comorbid eczema (ever) 
N (% not missing) 667(100) 
No, n (%) 601 (90.1) 
Yes, n (%) 66 (9.9) 
Comorbid GERD 
N (% not missing) 667(100) 
No, n (%) 470 (70.5) 
Yes, n (%) 197 (29.5) 
Comorbid GERD (ever) 
N (% not missing) 667(100) 
No, n (%) 367 (55.0) 
Yes, n (%) 300 (45.0) 
Ischaemic heart disease 
N (% not missing) 667(100) 
No, n (%) 613 (91.9) 
Yes, n (%) 54 (8.1) 
Ischaemic heart disease (ever) 
N (% not missing) 667(100) 
No, n (%) 584 (87.6) 
Yes, n (%) 83 (12.4) 
Influenza 
N (% not missing) 667(100) 
No, n (%) 654 (98.1) 
Yes, n (%) 13 (1.9) 
Influenza (ever) 
N (% not missing) 667(100) 
No, n (%) 645 (96.7) 
Yes, n (%) 22 (3.3) 
Other chronic lung diseases 
N (% not missing) 667(100) 
No, n (%) 407 (61.0) 
Yes, n (%) 260 (39.0) 
Other chronic lung diseases (ever) 
N (% not missing) 667(100) 
No, n (%) 292 (43.8) 
 Measure Patients changing from DPI to pMDI 
Yes, n (%) 375 (56.2) 
Comorbid nasal polyps 
N (% not missing) 667(100) 
No, n (%) 653 (97.9) 
Yes, n (%) 14 (2.1) 
Comorbid nasal polyps (ever) 
N (% not missing) 667(100) 
No, n (%) 640 (96.0) 
Yes, n (%) 27 (4.0) 
Pneumonia 
N (% not missing) 667(100) 
No, n (%) 606 (90.9) 
Yes, n (%) 61 (9.1) 
Pneumonia (ever) 
N (% not missing) 667(100) 
No, n (%) 562 (84.3) 
Yes, n (%) 105 (15.7) 
Comorbid rhinitis (active) 
N (% not missing) 667(100) 
No, n (%) 241 (36.1) 
Yes, n (%) 426 (63.9) 
Comorbid rhinitis (ever) 
N (% not missing) 667(100) 
No, n (%) 146 (21.9) 
Yes, n (%) 521 (78.1) 
Charlson Comorbidity Index (CCI) 
N (% not missing) 667 (100.0) 
Mean (SD) 1.4 (0.9) 
Median (IQR) 1 (1, 1) 
Min, Max (0, 7) 
Charlson Comorbidity Index (CCI) 
(categorised) 
N (% not missing) 667(100) 
0-1, n (%) 531 (79.6) 
2-5, n (%) 133 (19.9) 
6-10 n (%) 3 (0.4) 
DISEASE SEVERITY & HEALTHCARE UTILIZATION 
 Measure Patients changing from DPI to pMDI 
All inpatient admissions N (% not missing) 667 (100.0) 
 Measure Patients changing from DPI to pMDI 
Mean (SD) 0.9 (1.8) 
Median (IQR) 0 (0, 1) 
Min, Max (0, 24) 
All inpatient admissions 
(categorised) 
N (% not missing) 667(100) 
0, n (%) 414 (62.1) 
1, n (%) 125 (18.7) 
2, n (%) 68 (10.2) 
3, n (%) 29 (4.3) 
≥4, n (%) 31 (4.6) 
All inpatient admissions days 
N (% not missing) 667 (100.0) 
Mean (SD) 8.3 (23.8) 
Median (IQR) 0 (0, 7) 
Min, Max (0, 312) 
All inpatient admissions days 
(categorised) 
N (% not missing) 667(100) 
1-3, n (%) 44 (17.4) 
4-6, n (%) 38 (15.0) 
7-13, n (%) 58 (22.9) 
≥14, n (%) 113 (44.7) 
LRTI-related inpatient admissions 
N (% not missing) 667 (100.0) 
Mean (SD) 0.3 (0.6) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 5) 
LRTI-related inpatient admissions 
(categorised) 
N (% not missing) 667(100) 
0, n (%) 543 (81.4) 
1, n (%) 93 (13.9) 
2, n (%) 22 (3.3) 
3, n (%) 5 (0.7) 
≥4, n (%) 4 (0.6) 
LRTI-related inpatient admissions 
days 
N (% not missing) 667 (100.0) 
Mean (SD) 3.0 (10.9) 
 Measure Patients changing from DPI to pMDI 
Median (IQR) 0 (0, 0) 
Min, Max (0, 161) 
LRTI-related inpatient admissions 
days (categorised) 
N (% not missing) 667 (100) 
1-3, n (%) 14 (11.3) 
4-6, n (%) 22 (17.7) 
7-13, n (%) 43 (34.7) 
≥14, n (%) 45 (36.3) 
Asthma-related inpatient 
admissions 
N (% not missing) 667 (100.0) 
Mean (SD) 0.2 (0.7) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 5) 
Asthma-related inpatient 
admissions (categorised) 
N (% not missing) 667 (100) 
0, n (%) 567 (85.0) 
1, n (%) 72 (10.8) 
2, n (%) 18 (2.7) 
3, n (%) 4 (0.6) 
≥4, n (%) 6 (0.9) 
Asthma-related inpatient 
admissions days 
N (% not missing) 667 (100.0) 
Mean (SD) 2.1 (7.6) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 99) 
Asthma-related inpatient 
admissions days (categorised) 
N (% not missing) 667 (100) 
1-3, n (%) 13 (13.0) 
4-6, n (%) 20 (20.0) 
7-13, n (%) 35 (35.0) 
≥14, n (%) 32 (32.0) 
Asthma exacerbation-related 
inpatient admissions 
N (% not missing) 667 (100.0) 
Mean (SD) 0.1 (0.4) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 5) 
 Measure Patients changing from DPI to pMDI 
Asthma exacerbation-related 
inpatient admissions (categorised) 
N (% not missing) 667 (100) 
0, n (%) 629 (94.3) 
1, n (%) 26 (3.9) 
2, n (%) 8 (1.2) 
3, n (%) 2 (0.3) 
≥4, n (%) 2 (0.3) 
Asthma exacerbation-related 
inpatient admissions days 
N (% not missing) 667 (100.0) 
Mean (SD) 0.9 (5.3) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 78) 
Asthma exacerbation-related 
inpatient admissions days 
(categorised) 
N (% not missing) 667 (100) 
1-3, n (%) 8 (21.1) 
4-6, n (%) 5 (13.2) 
7-13, n (%) 11 (28.9) 
≥14, n (%) 14 (36.8) 
All outpatient attendances 
N (% not missing) 667 (100.0) 
Mean (SD) 33.7 (26.9) 
Median (IQR) 27 (16, 41) 
Min, Max (2, 220) 
All outpatient attendances 
(categorised) 
N (% not missing) 667(100) 
1-12, n (%) 88 (13.2) 
13-24, n (%) 221 (33.1) 
25-36, n (%) 149 (22.3) 
37-48, n (%) 91 (13.6) 
≥48, n (%) 118 (17.7) 
LRTI-related outpatient attendances 
N (% not missing) 667 (100.0) 
Mean (SD) 28.9 (23.9) 
Median (IQR) 22 (14, 35) 
Min, Max (2, 216) 
N (% not missing) 667 (100) 
 Measure Patients changing from DPI to pMDI 
LRTI-related outpatient attendances 
(categorised) 
1-12, n (%) 120 (18.0) 
13-24, n (%) 251 (37.6) 
25-36, n (%) 141 (21.1) 
37-48, n (%) 72 (10.8) 
≥48, n (%) 83 (12.4) 
Asthma-related outpatient 
attendances 
N (% not missing) 667 (100.0) 
Mean (SD) 7.3 (7.6) 
Median (IQR) 6 (3, 9) 
Min, Max (0, 85) 
Asthma-related outpatient 
attendances (categorised) 
N (% not missing) 667 (100) 
0, n (%) 47 (7.0) 
1-3, n (%) 146 (21.9) 
4-6, n (%) 184 (27.6) 
7-9, n (%) 129 (19.3) 
10-12, n (%) 65 (9.7) 
≥13, n (%) 96 (14.4) 
All emergency attendances 
N (% not missing) 667 (100.0) 
Mean (SD) 0.4 (0.9) 
Median (IQR) 0 (0, 1) 
Min, Max (0, 11) 
All emergency attendances 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 497 (74.5) 
1, n (%) 119 (17.8) 
2, n (%) 38 (5.7) 
3, n (%) 5 (0.7) 
≥4, n (%) 8 (1.2) 
LRTI-related emergency attendances 
N (% not missing) 667 (100.0) 
Mean (SD) 0.4 (0.8) 
Median (IQR) 0 (0, 1) 
Min, Max (0, 9) 
 Measure Patients changing from DPI to pMDI 
LRTI-related emergency attendances 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 497 (74.5) 
1, n (%) 123 (18.4) 
2, n (%) 35 (5.2) 
3, n (%) 5 (0.7) 
≥4, n (%) 7 (1.0) 
Asthma-related emergency 
attendances 
N (% not missing) 667 (100.0) 
Mean (SD) 0.1 (0.4) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 4) 
Asthma-related emergency 
attendances (categorised) 
N (% not missing) 667 (100) 
0, n (%) 603 (90.4) 
1, n (%) 51 (7.6) 
2, n (%) 10 (1.5) 
3, n (%) 2 (0.3) 
≥4, n (%) 1 (0.1) 
Antibiotics 
N (% not missing) 667 (100.0) 
Mean (SD) 1.2 (2.1) 
Median (IQR) 0 (0, 2) 
Min, Max (0, 15) 
Antibiotics (categorised) 
N (% not missing) 667 (100) 
0, n (%) 375 (56.2) 
1-3, n (%) 224 (33.6) 
4-6, n (%) 43 (6.4) 
7-9, n (%) 19 (2.8) 
10-12, n (%) 3 (0.4) 
≥13, n (%) 3 (0.4) 
Acute OCS 
N (% not missing) 667 (100.0) 
Mean (SD) 1.2 (2.4) 
Median (IQR) 0 (0, 1) 
 Measure Patients changing from DPI to pMDI 
Min, Max (0, 18) 
Acute OCS (categorised) 
N (% not missing) 667 (100) 
0, n (%) 408 (61.2) 
1, n (%) 107 (16.0) 
2, n (%) 47 (7.0) 
3, n (%) 38 (5.7) 
≥4, n (%) 67 (10.0) 
Non-acute OCS 
N (% not missing) 667 (100.0) 
Mean (SD) 0.6 (1.2) 
Median (IQR) 0 (0, 1) 
Min, Max (0, 9) 
Non-acute OCS (categorised) 
N (% not missing) 667 (100) 
0, n (%) 450 (67.5) 
1, n (%) 107 (16.0) 
2, n (%) 49 (7.3) 
3, n (%) 37 (5.5) 
≥4, n (%) 24 (3.6) 
MEDICATION USE DURING BASELINE YEAR 
 Measure Patients changing from DPI to pMDI 
FDC ICS/LABA prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 4.7 (2.7) 
Median (IQR) 4 (3, 6) 
Min, Max (2, 14) 
FDC ICS/LABA prescriptions 
(categorised) 
N (% not missing) 667 (100) 
2-3, n (%) 288 (43.2) 
≥4, n (%) 379 (56.8) 
ICS only prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 0.5 (1.4) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 18) 
 Measure Patients changing from DPI to pMDI 
ICS only prescriptions (yes/no) 
N (% not missing) 667(100) 
No, n (%) 504 (75.6) 
Yes, n (%) 163 (24.4) 
ICS only prescriptions 
(categorised) 
N (% not missing) 667(100) 
0, n (%) 504 (75.6) 
1, n (%) 90 (13.5) 
2, n (%) 40 (6.0) 
3, n (%) 10 (1.5) 
≥4, n (%) 23 (3.4) 
ICS average daily dose 
N (% not missing) 667 (100.0) 
Mean (SD) 400.8 (279.3) 
Median (IQR) 328.8 (205.5, 498.1) 
Min, Max (65.8, 2219.2) 
ICS average daily dose 
(categorised) 
N (% not missing) 667(100) 
>0-250, n (%) 243 (36.4) 
>250-500, n (%) 259 (38.8) 
>500, n (%) 165 (24.7) 
IV/IM CS prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 2.3 (4.5) 
Median (IQR) 1 (0, 3) 
Min, Max (0, 48) 
IV/IM CS prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 294 (44.1) 
Yes, n (%) 373 (55.9) 
IV/IM CS prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 294 (44.1) 
1-3, n (%) 244 (36.6) 
4-8, n (%) 87 (13.0) 
9-13, n (%) 20 (3.0) 
≥13, n (%) 22 (3.3) 
 Measure Patients changing from DPI to pMDI 
SABA prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 3.3 (6.5) 
Median (IQR) 1 (0, 3) 
Min, Max (0, 64) 
SABA prescriptions (yes/no) 
N (% not missing) 667 (100) 
No, n (%) 245 (36.7) 
Yes, n (%) 422 (63.3) 
SABA prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 245 (36.7) 
1-3, n (%) 260 (39.0) 
4-6, n (%) 65 (9.7) 
7-9, n (%) 34 (5.1) 
10-12, n (%) 26 (3.9) 
≥13, n (%) 37 (5.5) 
SABA inhaler prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 1.8 (4.2) 
Median (IQR) 0 (0, 1) 
Min, Max (0, 64) 
SABA inhaler prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 368 (55.2) 
Yes, n (%) 299 (44.8) 
SABA inhaler prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 368 (55.2) 
1-3, n (%) 201 (30.1) 
4-6, n (%) 44 (6.6) 
7-9, n (%) 24 (3.6) 
10-12, n (%) 14 (2.1) 
≥13, n (%) 16 (2.4) 
SABA inhaler average daily 
dose 
N (% not missing) 667 (100.0) 
Mean (SD) 138.0 (405.5) 
 Measure Patients changing from DPI to pMDI 
Median (IQR) 0 (0, 110) 
Min, Max (0, 6630) 
SABA inhaler average daily 
dose (categorised) 
N (% not missing) 667 (100) 
0, n (%) 368 (55.2) 
>0-200, n (%) 193 (28.9) 
>200-400, n (%) 43 (6.4) 
>400-800, n (%) 34 (5.1) 
≥800, n (%) 29 (4.3) 
SABA nebuliser prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 1.0 (3.2) 
Median (IQR) 0 (0, 1) 
Min, Max (0, 44) 
SABA nebuliser prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 427 (64.0) 
Yes, n (%) 240 (36.0) 
SABA nebuliser prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 427 (64.0) 
1-3, n (%) 200 (30.0) 
4-6, n (%) 23 (3.4) 
7-9, n (%) 4 (0.6) 
10-12, n (%) 5 (0.7) 
≥13, n (%) 8 (1.2) 
SABA oral prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 0.5 (2.0) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 24) 
SABA oral prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 579 (86.8) 
Yes, n (%) 88 (13.2) 
N (% not missing) 667 (100) 
 Measure Patients changing from DPI to pMDI 
SABA oral prescriptions 
(categorised) 
0, n (%) 579 (86.8) 
1-3, n (%) 66 (9.9) 
4-6, n (%) 10 (1.5) 
7-9, n (%) 5 (0.7) 
10-12, n (%) 4 (0.6) 
≥13, n (%) 3 (0.4) 
FDC SABA/SAMA prescriptions 
(yes/no) 
N (% not missing) 667 (100.0) 
Mean (SD) 0.0 (0.0) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 1) 
SAMA prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 0.7 (2.8) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 44) 
SAMA prescriptions (yes/no) 
N (% not missing) 667 (100) 
No, n (%) 524 (78.6) 
Yes, n (%) 143 (21.4) 
SAMA prescriptions 
(categorised) 
N (% not missing) 667(100) 
0, n (%) 524 (78.6) 
1, n (%) 83 (12.4) 
2, n (%) 26 (3.9) 
3, n (%) 9 (1.3) 
≥4, n (%) 25 (3.7) 
LAMA prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 1.5 (3.1) 
Median (IQR) 0 (0, 1) 
Min, Max (0, 14) 
LAMA prescriptions (yes/no) 
N (% not missing) 667 (100) 
No, n (%) 498 (74.7) 
Yes, n (%) 169 (25.3) 
 Measure Patients changing from DPI to pMDI 
LAMA prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 498 (74.7) 
1-2, n (%) 28 (4.2) 
3-4, n (%) 50 (7.5) 
≥5, n (%) 91 (13.6) 
FDC LABA/LAMA prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 667 (100.0) 
LABA inhaler prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 0.1 (0.6) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 10) 
LABA inhaler prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 651 (97.6) 
Yes, n (%) 16 (2.4) 
LABA inhaler prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 651 (97.6) 
1, n (%) 9 (1.3) 
2, n (%) 2 (0.3) 
3, n (%) 1 (0.1) 
≥4, n (%) 4 (0.6) 
LABA oral prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 1.3 (3.2) 
Median (IQR) 0 (0, 1) 
Min, Max (0, 34) 
LABA oral prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 463 (69.4) 
Yes, n (%) 204 (30.6) 
LABA oral prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 463 (69.4) 
1-3, n (%) 126 (18.9) 
 Measure Patients changing from DPI to pMDI 
4-6, n (%) 37 (5.5) 
7-11, n (%) 26 (3.9) 
≥12, n (%) 15 (2.2) 
LABA patch prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 0.3 (1.3) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 12) 
LABA patch prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 605 (90.7) 
Yes, n (%) 62 (9.3) 
LABA patch prescriptions 
(categorised) 
N (% not missing) 667(100) 
0, n (%) 605 (90.7) 
1-2, n (%) 38 (5.7) 
3-4, n (%) 9 (1.3) 
5-6, n (%) 4 (0.6) 
≥7, n (%) 11 (1.6) 
LTRA prescriptions 
N (% not missing) 667 (100.0) 
Mean (SD) 5.0 (5.5) 
Median (IQR) 4 (0, 8) 
Min, Max (0, 58) 
LTRA prescriptions (yes/no) 
N (% not missing) 667 (100) 
No, n (%) 180 (27.0) 
Yes, n (%) 487 (73.0) 
LTRA prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 180 (27.0) 
1-3, n (%) 132 (19.8) 
4-6, n (%) 153 (22.9) 
7-11, n (%) 119 (17.8) 
≥12, n (%) 83 (12.4) 
N (% not missing) 667 (100.0) 
 Measure Patients changing from DPI to pMDI 
Theophylline or other 
methylxanthine prescriptions 
Mean (SD) 4.6 (5.7) 
Median (IQR) 3 (0, 7) 
Min, Max (0, 65) 
Theophylline or other 
methylxanthine prescriptions 
(yes/no) 
N (% not missing) 667 (100) 
No, n (%) 198 (29.7) 
Yes, n (%) 469 (70.3) 
Theophylline or other 
methylxanthine prescriptions 
(categorised) 
N (% not missing) 667 (100) 
0, n (%) 198 (29.7) 
1-3, n (%) 170 (25.5) 
4-6, n (%) 115 (17.2) 
7-11, n (%) 107 (16.0) 
≥12, n (%) 77 (11.5) 
ASTHMA RELATED COST 
 Measure Patients changing from DPI to pMDI 
FDC ICS/LABA cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 331480.1 (216955.7) 
Min, Max (86950, 3437952) 
ICS only cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 6992.5 (24096.8) 
Min, Max (0, 248624) 
IV/IM CS cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 5056.9 (16060.6) 
Min, Max (0, 186724) 
SABA inhaler cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 10143.6 (29869.2) 
Min, Max (0, 487378) 
SABA oral cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 788.7 (10713.3) 
Median (IQR) 0 (0, 0) 
Min, Max (0, 266640) 
 Measure Patients changing from DPI to pMDI 
SABA nebuliser cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 2094.3 (11049.5) 
Min, Max (0, 193129) 
FDC SABA/SAMA cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 11.6 (298.6) 
Min, Max (0, 7713) 
SAMA cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 2525.8 (10455.3) 
Min, Max (0, 174540) 
LAMA cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 84249.3 (176232.2) 
Min, Max (0, 811740) 
LABA/LAMA cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 0.0 (0.0) 
Min, Max (0, 0) 
LABA inhaler cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 2511.6 (22363.8) 
Min, Max (0, 388800) 
LABA oral cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 5113.2 (19197.3) 
Min, Max (0, 218400) 
LABA patch cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 2294.2 (14596.3) 
Min, Max (0, 205920) 
LTRA cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 116117.7 (132790.5) 
Min, Max (0, 554140) 
Theophylline or other 
methylxanthine cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 23493.8 (34530.8) 
Min, Max (0, 159642) 
 Measure Patients changing from DPI to pMDI 
Acute OCS cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 1913.7 (9842.8) 
Min, Max (0, 209562) 
Non-acute OCS cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 399.7 (1768.2) 
Min, Max (0, 36360) 
Antibiotics cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 51814.0 (238078.8) 
Min, Max (0, 5092382) 
All inpatient admissions cost 
(KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 1499861.0 (4097685.5) 
Min, Max (0, 53905540) 
LRTI-related inpatient 
admissions cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 581952.0 (2343977.4) 
Min, Max (0, 43951550) 
Asthma-related inpatient 
admissions cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 338353.1 (1104294.1) 
Min, Max (0, 11255030) 
Asthma exacerbation-related 
inpatient admissions cost 
(KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 147886.4 (796022.2) 
Min, Max (0, 11255030) 
All outpatient attendances 
cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 969568.8 (1331032.1) 
Min, Max (66520, 24875180) 
LRTI-related outpatient 
attendances cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 969568.8 (1331032.1) 
Min, Max (66520, 24875180) 
Asthma-related outpatient 
attendances cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 177838.8 (185737.7) 
Min, Max (0, 1662900) 
 Measure Patients changing from DPI to pMDI 
All emergency attendances 
cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 572961.8 (2386341.7) 
Min, Max (0, 42381850) 
LRTI-related emergency 
attendances cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 572961.8 (2386341.7) 
Min, Max (0, 42381850) 
Asthma-related emergency 
attendances cost (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 142548.1 (701601.2) 
Min, Max (0, 9598590) 
All hospitalisation costs (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 3042391.5 (6501754.7) 
Min, Max (66520, 97633700) 
All asthma-related 
hospitalisation costs (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 1690417.0 (3115036.8) 
Min, Max (66520, 43728160) 
Drug costs (without ICS) 
(KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 318297.8 (380091.2) 
Min, Max (0, 5260946) 
Drug costs (with ICS) (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 656770.4 (494364.0) 
Min, Max (100040, 5584425) 
Total costs (without ICS) 
(KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 2008714.8 (3330415.6) 
Min, Max (72455, 48989106) 
Total costs (with ICS) (KRW) 
N (% not missing) 667 (100.0) 
Mean (SD) 2347187.3 (3361235.4) 
Min, Max (220157, 49312585) 
 
  
Table A7: Detailed results outcome 2 
  Measure Baseline Outcome OR (95%CI) p-value 
Severe 
exacerbations 
(ATS/ERS) 
N (% not missing) 667 (100.0) 667 (100.0) 
1.561 (1.314, 
1.856)† <0.001
† 
Mean (SD) 0.6 (0.8) 1.0 (2.3) 
Median (IQR) 1 (0, 1) 0 (0, 1) 
Min, Max (0, 6) (0, 39) 
Severe 
exacerbations 
(ATS/ERS) 
(categorised) 
N (% not missing) 667 (100.0) 667 (100.0) 
Data visualisation only 
0, n (%) 316 (47.4) 389 (58.3) 
1, n (%) 295 (44.2) 131 (19.6) 
2, n (%) 42 (6.3) 70 (10.5) 
3, n (%) 7 (1.0) 24 (3.6) 
≥4, n (%) 7 (1.0) 53 (7.9) 
Acute 
respiratory 
event 
N (% not missing) 667 (100.0) 667 (100.0) 
1.308 (1.137, 
1.504)† <0.001
† 
Mean (SD) 1.2 (1.5) 1.6 (2.6) 
Median (IQR) 1 (0, 1) 1 (0, 2) 
Min, Max (0, 12) (0, 39) 
Acute 
respiratory 
event 
(categorised) 
N (% not missing) 667 (100.0) 667 (100.0) 
Data visualisation only 
0, n (%) 219 (32.8) 302 (45.3) 
1, n (%) 291 (43.6) 144 (21.6) 
2, n (%) 83 (12.4) 77 (11.5) 
3, n (%) 24 (3.6) 47 (7.0) 
≥4, n (%) 50 (7.5) 97 (14.5) 
Risk domain 
asthma control 
N (% not missing) 667 (100.0) 667 (100.0) 
1.112 (0.969, 
1.275)∆ 0.131
∆ No, n (%) 406 (60.9) 389 (58.3) 
Yes, n (%) 261 (39.1) 278 (41.7) 
Overall asthma 
control 
N (% not missing) 667 (100.0) 667 (100.0) 
1.183 (1.022, 
1.369)∆ 0.024
∆ No, n (%) 435 (65.2) 409 (61.3) 
Yes, n (%) 232 (34.8) 258 (38.7) 
Asthma 
exacerbation-
related 
inpatient 
admissions 
N (% not missing) 667 (100.0) 667 (100.0) 
0.776 (0.422, 
1.425)† 0.413
† 
Mean (SD) 0.1 (0.4) 0.1 (0.5) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 5) (0, 10) 
  Measure Baseline Outcome OR (95%CI) p-value 
Asthma 
exacerbation-
related 
inpatient 
admissions 
(categorised) 
N (% not missing) 667 (100.0) 667 (100.0) 
Data visualisation only 
0, n (%) 629 (94.3) 640 (96.0) 
1, n (%) 26 (3.9) 20 (3.0) 
2, n (%) 8 (1.2) 4 (0.6) 
3, n (%) 2 (0.3) 1 (0.1) 
≥4, n (%) 2 (0.3) 2 (0.3) 
SABA inhaler 
average daily 
dose, µg 
(categorised) 
N (% not missing) 667 (100.0) 667 (100.0) 
0.505 (0.432, 
0.589)‡ <0.001
‡ 
0, n (%) 368 (55.2) 480 (72.0) 
>0-200, n (%) 193 (28.9) 113 (16.9) 
>200-400, n (%) 43 (6.4) 32 (4.8) 
>400-800, n (%) 34 (5.1) 28 (4.2) 
>800, n (%) 29 (4.3) 14 (2.1) 
Oral thrush 
N (% not missing) 667 (100.0) 667 (100.0) 
0.352 (0.141, 
0.881)∆ 0.026
∆ No, n (%) 653 (97.9) 662 (99.3) 
Yes, n (%) 14 (2.1) 5 (0.7) 
ICS average 
daily dose, µg 
(categorised) 
N (% not missing) 667 (100.0) 667 (100.0) 
1.008 (0.875, 
1.161)‡ 0.913
‡ 
>0-250, n (%) 243 (36.4) 257 (38.5) 
>250-500, n (%) 259 (38.8) 226 (33.9) 
>500, n (%) 165 (24.7) 184 (27.6) 
Treatment 
stability 
N (% not missing) 
N/A 
667 (100.0) 
N/A N/A No, n (%) 394 (59.1) 
Yes, n (%) 273 (40.9) 
∆ Conditional binary logistic regression (unadjusted); ‡ Conditional ordinal logistic regression (unadjusted); † 
Conditional Poisson regression (unadjusted); N/A – not applicable (no hypothesis testing conducted); All odds 
ratios have baseline as the reference category. 
  
Table A8: Baseline characteristics outcome 3 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
Age at IPD 
(years) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.002 0.001 
Mean (SD) 58.6 (14.7) 58.6 (14.8) 
Median (IQR) 61 (50, 71) 61 (50, 71) 
Min, Max (12, 80) (12, 80) 
Age at IPD 
(years) 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.009 0.008 
12-18, n (%) 14 (0.7) 2 (0.3) 
19-35, n (%) 155 (8.0) 55 (8.6) 
36-65, n (%) 1012 (52.5) 335 (52.2) 
66-80, n (%) 745 (38.7) 250 (38.9) 
Gender 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.000 0.000 Male, n (%) 1062 (55.1) 354 (55.1) 
Female, n (%) 864 (44.9) 288 (44.9) 
Insurance 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.076 0.004 
Medical insurance, n (%) 1678 (87.1) 565 (88.0) 
Medical aid, n (%) 220 (11.4) 75 (11.7) 
Veterans cover, n (%) 28 (1.5) 2 (0.3) 
COMORBIDITIES 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
COPD 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.000 0.000 No, n (%) 717 (37.2) 239 (37.2) 
Yes, n (%) 1209 (62.8) 403 (62.8) 
COPD (ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.143 0.005 No, n (%) 629 (32.7) 168 (26.2) 
Yes, n (%) 1297 (67.3) 474 (73.8) 
Oral thrush 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.059 0.006 No, n (%) 1913 (99.3) 634 (98.8) 
Yes, n (%) 13 (0.7) 8 (1.2) 
Oral thrush (ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.111 0.009 
No, n (%) 1910 (99.2) 628 (97.8) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
Yes, n (%) 16 (0.8) 14 (2.2) 
Comorbid eczema 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.062 0.001 No, n (%) 1816 (94.3) 614 (95.6) 
Yes, n (%) 110 (5.7) 28 (4.4) 
Comorbid eczema 
(ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.060 0.004 No, n (%) 1770 (91.9) 579 (90.2) 
Yes, n (%) 156 (8.1) 63 (9.8) 
Comorbid GERD 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.104 0.006 No, n (%) 1459 (75.8) 457 (71.2) 
Yes, n (%) 467 (24.2) 185 (28.8) 
Comorbid GERD 
(ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.264 0.008 No, n (%) 1319 (68.5) 358 (55.8) 
Yes, n (%) 607 (31.5) 284 (44.2) 
Ischaemic heart 
disease 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.002 0.000 No, n (%) 1774 (92.1) 591 (92.1) 
Yes, n (%) 152 (7.9) 51 (7.9) 
Ischaemic heart 
disease (ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.098 0.003 No, n (%) 1745 (90.6) 562 (87.5) 
Yes, n (%) 181 (9.4) 80 (12.5) 
Influenza 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.095 0.003 No, n (%) 1909 (99.1) 629 (98.0) 
Yes, n (%) 17 (0.9) 13 (2.0) 
Influenza (ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.101 0.004 No, n (%) 1891 (98.2) 620 (96.6) 
Yes, n (%) 35 (1.8) 22 (3.4) 
Other chronic lung 
diseases 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.024 0.001 No, n (%) 1210 (62.8) 396 (61.7) 
Yes, n (%) 716 (37.2) 246 (38.3) 
Other chronic lung 
diseases (ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.215 0.010 
No, n (%) 1064 (55.2) 286 (44.5) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
Yes, n (%) 862 (44.8) 356 (55.5) 
Comorbid nasal 
polyps 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.004 0.000 No, n (%) 1888 (98.0) 629 (98.0) 
Yes, n (%) 38 (2.0) 13 (2.0) 
Comorbid nasal 
polyps (ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.073 0.002 No, n (%) 1876 (97.4) 617 (96.1) 
Yes, n (%) 50 (2.6) 25 (3.9) 
Pneumonia 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.027 0.005 No, n (%) 1674 (86.9) 552 (86.0) 
Yes, n (%) 252 (13.1) 90 (14.0) 
Pneumonia (ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.096 0.016 No, n (%) 1591 (82.6) 506 (78.8) 
Yes, n (%) 335 (17.4) 136 (21.2) 
Comorbid rhinitis 
(active) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.133 0.000 No, n (%) 821 (42.6) 232 (36.1) 
Yes, n (%) 1105 (57.4) 410 (63.9) 
Comorbid rhinitis 
(ever) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.315 0.010 No, n (%) 702 (36.4) 143 (22.3) 
Yes, n (%) 1224 (63.6) 499 (77.7) 
Charlson 
Comorbidity Index 
(CCI) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.018 0.003 
Mean (SD) 1.4 (0.9) 1.4 (0.9) 
Median (IQR) 1 (1, 1) 1 (1, 1) 
Min, Max (0, 7) (0, 6) 
Charlson 
Comorbidity Index 
(CCI) (categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.024 0.003 
0-1, n (%) 1546 (80.3) 508 (79.1) 
2-5, n (%) 371 (19.3) 132 (20.6) 
6-10 n (%) 9 (0.5) 2 (0.3) 
DISEASE SEVERITY & HEALTHCARE UTILIZATION 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
N (% not missing) 1926 (100.0) 642 (100.0) 0.075 0.006 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
All inpatient 
admissions 
Mean (SD) 0.7 (1.5) 0.8 (1.7) 
Median (IQR) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 24) (0, 24) 
All inpatient 
admissions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.087 0.008 
0, n (%) 1308 (67.9) 402 (62.6) 
1, n (%) 332 (17.2) 122 (19.0) 
2, n (%) 149 (7.7) 65 (10.1) 
3, n (%) 46 (2.4) 27 (4.2) 
≥4, n (%) 91 (4.7) 26 (4.0) 
All inpatient 
admissions days 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.073 0.002 
Mean (SD) 5.9 (19.9) 7.4 (21.6) 
Median (IQR) 0 (0, 4) 0 (0, 6) 
Min, Max (0, 380) (0, 312) 
All inpatient 
admissions days 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
Data 
visualisation 
only 
0, n (%) 1308 (67.9) 402 (62.6) 
1-3, n (%) 112 (5.8) 43 (6.7) 
4-6, n (%) 108 (5.6) 38 (5.9) 
7-13, n (%) 182 (9.4) 56 (8.7) 
≥14, n (%) 216 (11.2) 103 (16.0) 
LRTI-related 
inpatient 
admissions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.031 0.005 
Mean (SD) 0.2 (0.6) 0.2 (0.6) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 5) (0, 5) 
LRTI-related 
inpatient 
admissions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.033 0.005 
0, n (%) 1609 (83.5) 527 (82.1) 
1, n (%) 246 (12.8) 88 (13.7) 
2, n (%) 48 (2.5) 21 (3.3) 
3, n (%) 17 (0.9) 3 (0.5) 
≥4, n (%) 6 (0.3) 3 (0.5) 
N (% not missing) 1926 (100.0) 642 (100.0) 0.049 0.002 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
LRTI-related 
inpatient 
admissions days 
Mean (SD) 2.3 (9.9) 2.8 (10.5) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 295) (0, 161) 
LRTI-related 
inpatient 
admissions days 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
Data 
visualisation 
only 
0, n (%) 1609 (83.5) 527 (82.1) 
1-3, n (%) 30 (1.6) 12 (1.9) 
4-6, n (%) 67 (3.5) 22 (3.4) 
7-13, n (%) 123 (6.4) 40 (6.2) 
≥14, n (%) 97 (5.0) 41 (6.4) 
Asthma-related 
inpatient 
admissions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.070 0.006 
Mean (SD) 0.2 (0.5) 0.2 (0.6) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 10) (0, 5) 
Asthma-related 
inpatient 
admissions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.070 0.000 
0, n (%) 1685 (87.5) 549 (85.5) 
1, n (%) 190 (9.9) 69 (10.7) 
2, n (%) 37 (1.9) 18 (2.8) 
3, n (%) 9 (0.5) 2 (0.3) 
≥4, n (%) 5 (0.3) 4 (0.6) 
Asthma-related 
inpatient 
admissions days 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.050 0.001 
Mean (SD) 1.5 (8.3) 1.9 (6.9) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 295) (0, 99) 
Asthma-related 
inpatient 
admissions days 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
Data 
visualisation 
only 
0, n (%) 1685 (87.5) 549 (85.5) 
1-3, n (%) 27 (1.4) 12 (1.9) 
4-6, n (%) 64 (3.3) 19 (3.0) 
7-13, n (%) 95 (4.9) 34 (5.3) 
≥14, n (%) 55 (2.9) 28 (4.4) 
N (% not missing) 1926 (100.0) 642 (100.0) 0.068 0.009 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
Asthma 
exacerbation-
related inpatient 
admissions 
Mean (SD) 0.1 (0.3) 0.1 (0.4) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 4) (0, 5) 
Asthma 
exacerbation-
related inpatient 
admissions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.065 0.006 
0, n (%) 1849 (96.0) 608 (94.7) 
1, n (%) 58 (3.0) 24 (3.7) 
2, n (%) 16 (0.8) 8 (1.2) 
3, n (%) 1 (0.1) 1 (0.2) 
≥4, n (%) 2 (0.1) 1 (0.2) 
Asthma 
exacerbation-
related inpatient 
admissions days 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.058 0.006 
Mean (SD) 0.5 (3.3) 0.7 (4.3) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 65) (0, 65) 
Asthma 
exacerbation-
related inpatient 
admissions days 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
Data 
visualisation 
only 
0, n (%) 1849 (96.0) 608 (94.7) 
1-3, n (%) 5 (0.3) 8 (1.2) 
4-6, n (%) 15 (0.8) 4 (0.6) 
7-13, n (%) 39 (2.0) 10 (1.6) 
≥14, n (%) 18 (0.9) 12 (1.9) 
All outpatient 
attendances 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.086 0.017 
Mean (SD) 31.3 (25.2) 33.6 (27.1) 
Median (IQR) 25 (15, 39) 27 (16, 41) 
Min, Max (2, 278) (2, 220) 
All outpatient 
attendances 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.080 0.023 
1-12, n (%) 327 (17.0) 88 (13.7) 
13-24, n (%) 630 (32.7) 210 (32.7) 
25-36, n (%) 429 (22.3) 146 (22.7) 
37-48, n (%) 226 (11.7) 86 (13.4) 
≥48, n (%) 314 (16.3) 112 (17.4) 
N (% not missing) 1926 (100.0) 642 (100.0) 0.092 0.020 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
LRTI-related 
outpatient 
attendances 
Mean (SD) 26.8 (21.9) 28.9 (24.1) 
Median (IQR) 21 (13, 33) 22 (14, 35) 
Min, Max (1, 275) (2, 216) 
LRTI-related 
outpatient 
attendances 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.089 0.016 
1-12, n (%) 419 (21.8) 119 (18.5) 
13-24, n (%) 722 (37.5) 239 (37.2) 
25-36, n (%) 397 (20.6) 136 (21.2) 
37-48, n (%) 180 (9.3) 69 (10.7) 
≥48, n (%) 208 (10.8) 79 (12.3) 
Asthma-related 
outpatient 
attendances 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.029 0.008 
Mean (SD) 7.4 (6.9) 7.2 (7.2) 
Median (IQR) 6 (3, 10) 6 (3, 9) 
Min, Max (0, 62) (0, 85) 
Asthma-related 
outpatient 
attendances 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.031 0.014 
0, n (%) 137 (7.1) 45 (7.0) 
1-3, n (%) 416 (21.6) 142 (22.1) 
4-6, n (%) 546 (28.3) 176 (27.4) 
7-9, n (%) 319 (16.6) 126 (19.6) 
10-12, n (%) 192 (10.0) 62 (9.7) 
≥13, n (%) 316 (16.4) 91 (14.2) 
All emergency 
attendances 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.012 0.001 
Mean (SD) 0.3 (0.8) 0.4 (0.9) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 13) (0, 11) 
All emergency 
attendances 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.001 0.010 
0, n (%) 1493 (77.5) 486 (75.7) 
1, n (%) 299 (15.5) 114 (17.8) 
2, n (%) 89 (4.6) 32 (5.0) 
3, n (%) 17 (0.9) 4 (0.6) 
≥4, n (%) 28 (1.5) 6 (0.9) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
LRTI-related 
emergency 
attendances 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.018 0.000 
Mean (SD) 0.3 (0.8) 0.3 (0.8) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 12) (0, 9) 
LRTI-related 
emergency 
attendances 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.007 0.009 
0, n (%) 1493 (77.5) 486 (75.7) 
1, n (%) 315 (16.4) 118 (18.4) 
2, n (%) 76 (3.9) 29 (4.5) 
3, n (%) 20 (1.0) 4 (0.6) 
≥4, n (%) 22 (1.1) 5 (0.8) 
Asthma-related 
emergency 
attendances 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.033 0.002 
Mean (SD) 0.1 (0.4) 0.1 (0.4) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 4) (0, 4) 
Asthma-related 
emergency 
attendances 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.033 0.002 
0, n (%) 1770 (91.9) 585 (91.1) 
1, n (%) 132 (6.9) 47 (7.3) 
2, n (%) 17 (0.9) 7 (1.1) 
3, n (%) 5 (0.3) 2 (0.3) 
≥4, n (%) 2 (0.1) 1 (0.2) 
Antibiotics 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.117 0.028 
Mean (SD) 0.9 (1.9) 1.2 (2.1) 
Median (IQR) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 29) (0, 15) 
Antibiotics 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.125 0.033 
0, n (%) 1190 (61.8) 366 (57.0) 
1-3, n (%) 600 (31.2) 210 (32.7) 
4-6, n (%) 99 (5.1) 42 (6.5) 
7-9, n (%) 18 (0.9) 18 (2.8) 
10-12, n (%) 12 (0.6) 3 (0.5) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
≥13, n (%) 7 (0.4) 3 (0.5) 
Acute OCS 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.030 0.015 
Mean (SD) 1.1 (2.3) 1.2 (2.4) 
Median (IQR) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 25) (0, 18) 
Acute OCS 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.007 0.001 
0, n (%) 1189 (61.7) 394 (61.4) 
1, n (%) 297 (15.4) 103 (16.0) 
2, n (%) 155 (8.0) 46 (7.2) 
3, n (%) 97 (5.0) 35 (5.5) 
≥4, n (%) 188 (9.8) 64 (10.0) 
Non-acute OCS 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.086 0.021 
Mean (SD) 0.7 (1.4) 0.6 (1.2) 
Median (IQR) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 21) (0, 9) 
Non-acute OCS 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.090 0.029 
0, n (%) 1251 (65.0) 435 (67.8) 
1, n (%) 306 (15.9) 104 (16.2) 
2, n (%) 150 (7.8) 45 (7.0) 
3, n (%) 115 (6.0) 35 (5.5) 
≥4, n (%) 104 (5.4) 23 (3.6) 
MEDICATION USE DURING BASELINE YEAR 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
FDC ICS/LABA 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.035 0.003 
Mean (SD) 4.8 (2.9) 4.7 (2.7) 
Median (IQR) 4 (2, 6) 4 (3, 6) 
Min, Max (2, 21) (2, 14) 
FDC ICS/LABA 
prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.005 0.000 2-3, n (%) 829 (43.0) 278 (43.3) 
≥4, n (%) 1097 (57.0) 364 (56.7) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
ICS only 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.036 0.006 
Mean (SD) 0.6 (2.0) 0.5 (1.2) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 47) (0, 10) 
ICS only 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.109 0.008 No, n (%) 1548 (80.4) 487 (75.9) 
Yes, n (%) 378 (19.6) 155 (24.1) 
ICS only 
prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.029 0.001 
0, n (%) 1548 (80.4) 487 (75.9) 
1, n (%) 187 (9.7) 87 (13.6) 
2, n (%) 74 (3.8) 38 (5.9) 
3, n (%) 37 (1.9) 10 (1.6) 
≥4, n (%) 80 (4.2) 20 (3.1) 
ICS average daily 
dose 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.049 0.004 
Mean (SD) 383.2 (274.2) 396.7 (279.5) 
Median (IQR) 328.8 (164.4, 493.2) 320.1 (198.9, 493.2) 
Min, Max (26.3, 2137.0) (65.8, 2219.2) 
ICS average daily 
dose (categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.000 0.000 
>0-250, n (%) 720 (37.4) 240 (37.4) 
>250-500, n (%) 741 (38.5) 247 (38.5) 
>500, n (%) 465 (24.1) 155 (24.1) 
IV/IM CS 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.068 0.009 
Mean (SD) 2.0 (4.1) 2.3 (4.5) 
Median (IQR) 1 (0, 2) 1 (0, 3) 
Min, Max (0, 73) (0, 48) 
IV/IM CS 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.071 0.003 No, n (%) 917 (47.6) 283 (44.1) 
Yes, n (%) 1009 (52.4) 359 (55.9) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.082 0.014 
0, n (%) 917 (47.6) 283 (44.1) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
IV/IM CS 
prescriptions 
(categorised) 
1-3, n (%) 682 (35.4) 237 (36.9) 
4-8, n (%) 232 (12.0) 82 (12.8) 
9-13, n (%) 51 (2.6) 19 (3.0) 
≥13, n (%) 44 (2.3) 21 (3.3) 
SABA prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.005 0.004 
Mean (SD) 3.1 (5.9) 3.0 (6.0) 
Median (IQR) 1 (0, 4) 1 (0, 3) 
Min, Max (0, 93) (0, 61) 
SABA prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.052 0.001 No, n (%) 769 (39.9) 240 (37.4) 
Yes, n (%) 1157 (60.1) 402 (62.6) 
SABA prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.015 0.018 
0, n (%) 769 (39.9) 240 (37.4) 
1-3, n (%) 660 (34.3) 255 (39.7) 
4-6, n (%) 219 (11.4) 61 (9.5) 
7-9, n (%) 108 (5.6) 31 (4.8) 
10-12, n (%) 71 (3.7) 24 (3.7) 
≥13, n (%) 99 (5.1) 31 (4.8) 
SABA inhaler 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.009 0.000 
Mean (SD) 1.5 (3.3) 1.6 (3.3) 
Median (IQR) 0 (0, 2) 0 (0, 1) 
Min, Max (0, 49) (0, 28) 
SABA inhaler 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.000 0.000 No, n (%) 1086 (56.4) 362 (56.4) 
Yes, n (%) 840 (43.6) 280 (43.6) 
SABA inhaler 
prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.016 0.000 
0, n (%) 1086 (56.4) 362 (56.4) 
1-3, n (%) 597 (31.0) 192 (29.9) 
4-6, n (%) 111 (5.8) 43 (6.7) 
7-9, n (%) 59 (3.1) 20 (3.1) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
10-12, n (%) 41 (2.1) 12 (1.9) 
≥13, n (%) 32 (1.7) 13 (2.0) 
SABA inhaler average 
daily dose 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.013 0.000 
Mean (SD) 121.1 (323.4) 116.9 (300.4) 
Median (IQR) 0 (0, 110) 0 (0, 55) 
Min, Max (0, 5534) (0, 3123) 
SABA inhaler average 
daily dose 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.000 0.000 
0, n (%) 1086 (56.4) 362 (56.4) 
>0-200, n (%) 561 (29.1) 187 (29.1) 
>200-400, n (%) 117 (6.1) 39 (6.1) 
>400-800, n (%) 96 (5.0) 32 (5.0) 
≥800, n (%) 66 (3.4) 22 (3.4) 
SABA nebuliser 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.019 0.000 
Mean (SD) 0.9 (3.7) 1.0 (3.2) 
Median (IQR) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 92) (0, 44) 
SABA nebuliser 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.121 0.012 No, n (%) 1354 (70.3) 415 (64.6) 
Yes, n (%) 572 (29.7) 227 (35.4) 
SABA nebuliser 
prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.074 0.004 
0, n (%) 1354 (70.3) 415 (64.6) 
1-3, n (%) 458 (23.8) 190 (29.6) 
4-6, n (%) 59 (3.1) 20 (3.1) 
7-9, n (%) 26 (1.3) 4 (0.6) 
10-12, n (%) 9 (0.5) 5 (0.8) 
≥13, n (%) 20 (1.0) 8 (1.2) 
SABA oral 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.054 0.010 
Mean (SD) 0.6 (2.6) 0.5 (2.1) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 46) (0, 24) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
SABA oral 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.015 0.001 No, n (%) 1670 (86.7) 560 (87.2) 
Yes, n (%) 256 (13.3) 82 (12.8) 
SABA oral 
prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.057 0.012 
0, n (%) 1670 (86.7) 560 (87.2) 
1-3, n (%) 154 (8.0) 61 (9.5) 
4-6, n (%) 57 (3.0) 9 (1.4) 
7-9, n (%) 15 (0.8) 5 (0.8) 
10-12, n (%) 12 (0.6) 4 (0.6) 
≥13, n (%) 18 (0.9) 3 (0.5) 
FDC SABA/SAMA 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.014 0.001 
Mean (SD) 0.0 (0.0) 0.0 (0.0) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 1) (0, 1) 
SAMA prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.118 0.006 
Mean (SD) 0.3 (2.0) 0.6 (2.7) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 72) (0, 44) 
SAMA prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.103 0.009 No, n (%) 1604 (83.3) 509 (79.3) 
Yes, n (%) 322 (16.7) 133 (20.7) 
SAMA prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.148 0.028 
0, n (%) 1604 (83.3) 509 (79.3) 
1, n (%) 221 (11.5) 80 (12.5) 
2, n (%) 57 (3.0) 22 (3.4) 
3, n (%) 20 (1.0) 9 (1.4) 
≥4, n (%) 24 (1.2) 22 (3.4) 
LAMA prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.028 0.007 Mean (SD) 1.4 (3.0) 1.5 (3.1) 
Median (IQR) 0 (0, 0) 0 (0, 1) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
Min, Max (0, 15) (0, 14) 
LAMA prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.045 0.007 No, n (%) 1477 (76.7) 480 (74.8) 
Yes, n (%) 449 (23.3) 162 (25.2) 
LAMA prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.013 0.009 
0, n (%) 1477 (76.7) 480 (74.8) 
1-2, n (%) 56 (2.9) 24 (3.7) 
3-4, n (%) 99 (5.1) 50 (7.8) 
≥5, n (%) 294 (15.3) 88 (13.7) 
LABA inhaler 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.147 0.003 
Mean (SD) 0.0 (0.1) 0.1 (0.6) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 3) (0, 10) 
LABA inhaler 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.186 0.013 No, n (%) 1920 (99.7) 626 (97.5) 
Yes, n (%) 6 (0.3) 16 (2.5) 
LABA inhaler 
prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.164 0.010 
0, n (%) 1920 (99.7) 626 (97.5) 
1, n (%) 3 (0.2) 9 (1.4) 
2, n (%) 2 (0.1) 2 (0.3) 
3, n (%) 1 (0.1) 1 (0.2) 
≥4, n (%) 0 (0.0) 4 (0.6) 
LABA oral 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.071 0.003 
Mean (SD) 1.6 (3.9) 1.3 (3.2) 
Median (IQR) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 41) (0, 34) 
LABA oral 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.003 0.001 No, n (%) 1350 (70.1) 449 (69.9) 
Yes, n (%) 576 (29.9) 193 (30.1) 
N (% not missing) 1926 (100.0) 642 (100.0) 0.051 0.002 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
LABA oral 
prescriptions 
(categorised) 
0, n (%) 1350 (70.1) 449 (69.9) 
1-3, n (%) 316 (16.4) 117 (18.2) 
4-6, n (%) 100 (5.2) 35 (5.5) 
7-11, n (%) 83 (4.3) 26 (4.0) 
≥12, n (%) 77 (4.0) 15 (2.3) 
LABA patch 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.005 0.004 
Mean (SD) 0.3 (1.4) 0.3 (1.3) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
Min, Max (0, 20) (0, 12) 
LABA patch 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.062 0.008 No, n (%) 1782 (92.5) 583 (90.8) 
Yes, n (%) 144 (7.5) 59 (9.2) 
LABA patch 
prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.029 0.002 
0, n (%) 1782 (92.5) 583 (90.8) 
1-2, n (%) 74 (3.8) 37 (5.8) 
3-4, n (%) 31 (1.6) 9 (1.4) 
5-6, n (%) 14 (0.7) 3 (0.5) 
≥7, n (%) 25 (1.3) 10 (1.6) 
LTRA prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.246 0.030 
Mean (SD) 3.7 (4.8) 4.9 (5.5) 
Median (IQR) 2 (0, 6) 4 (0, 7) 
Min, Max (0, 42) (0, 58) 
LTRA prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.276 0.020 No, n (%) 781 (40.6) 177 (27.6) 
Yes, n (%) 1145 (59.4) 465 (72.4) 
LTRA prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.279 0.026 
0, n (%) 781 (40.6) 177 (27.6) 
1-3, n (%) 387 (20.1) 129 (20.1) 
4-6, n (%) 330 (17.1) 146 (22.7) 
7-11, n (%) 273 (14.2) 110 (17.1) 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
≥12, n (%) 155 (8.0) 80 (12.5) 
Theophylline or 
other 
methylxanthines 
prescriptions 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.033 0.008 
Mean (SD) 4.8 (6.6) 4.6 (5.8) 
Median (IQR) 3 (0, 7) 3 (0, 7) 
Min, Max (0, 90) (0, 65) 
Theophylline or 
other 
methylxanthines 
prescriptions 
(yes/no) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.089 0.001 No, n (%) 656 (34.1) 192 (29.9) 
Yes, n (%) 1270 (65.9) 450 (70.1) 
Theophylline or 
other 
methylxanthines 
prescriptions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.015 0.014 
0, n (%) 656 (34.1) 192 (29.9) 
1-3, n (%) 418 (21.7) 163 (25.4) 
4-6, n (%) 289 (15.0) 112 (17.4) 
7-11, n (%) 326 (16.9) 100 (15.6) 
≥12, n (%) 237 (12.3) 75 (11.7) 
ASTHMA RELATED COST DURING BASELINE YEAR 
 
 
Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
FDC ICS/LABA 
cost (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.219 0.017 Mean (SD) 378887.3 (221267.5) 330670.1 (218664.9) 
Min, Max (74658, 2176464) (86950, 3437952) 
ICS only cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.074 0.003 Mean (SD) 5164.1 (23375.5) 6897.6 (23787.3) 
Min, Max (0, 461849) (0, 248624) 
IV/IM CS cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.059 0.015 Mean (SD) 3835.5 (15215.2) 4727.7 (15076.6) 
Min, Max (0, 283017) (0, 186724) 
SABA inhaler 
cost (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.019 0.000 Mean (SD) 9065.6 (24145.6) 8627.7 (22334.5) 
Min, Max (0, 420527) (0, 237234) 
N (% not missing) 1926 (100.0) 642 (100.0) 0.056 0.003 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
SABA oral cost 
(KRW) 
Mean (SD) 1487.2 (13168.9) 810.4 (10918.9) 
Min, Max (0, 283416) (0, 266640) 
SABA nebuliser 
cost (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.032 0.006 Mean (SD) 1710.1 (10353.8) 2050.9 (11228.2) 
Min, Max (0, 231609) (0, 193129) 
FDC SABA/SAMA 
cost (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.005 0.001 Mean (SD) 14.0 (456.9) 12.0 (304.4) 
Min, Max (0, 17938) (0, 7713) 
SAMA cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.024 0.006 Mean (SD) 2117.0 (12398.2) 2385.9 (10210.0) 
Min, Max (0, 346740) (0, 174540) 
LAMA cost (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.053 0.001 Mean (SD) 95415.5 (203721.7) 85281.5 (177227.7) 
Min, Max (0, 1721882) (0, 811740) 
LABA inhaler cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.147 0.003 Mean (SD) 201.9 (3957.9) 2609.4 (22790.2) 
Min, Max (0, 116640) (0, 388800) 
LABA oral cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.104 0.001 Mean (SD) 7755.1 (27824.8) 5250.0 (19544.9) 
Min, Max (0, 374820) (0, 218400) 
LABA patch cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.031 0.003 Mean (SD) 2803.6 (22785.6) 2210.1 (14601.6) 
Min, Max (0, 473287) (0, 205920) 
LTRA cost (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.048 0.003 Mean (SD) 122012.9 (180989.6) 114401.3 (131995.2) 
Min, Max (0, 1245896) (0, 554140) 
Theophylline or 
other 
methylxanthine 
cost (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.135 0.017 Mean (SD) 29165.5 (45331.9) 23698.4 (34812.1) 
Min, Max (0, 400303) (0, 159642) 
N (% not missing) 1926 (100.0) 642 (100.0) 0.007 0.008 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
Acute OCS cost 
(KRW) 
Mean (SD) 2021.7 (10166.0) 1950.9 (10021.4) 
Min, Max (0, 278100) (0, 209562) 
Non-acute OCS 
cost (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.053 0.006 Mean (SD) 608.6 (5436.9) 395.4 (1789.0) 
Min, Max (0, 225408) (0, 36360) 
Antibiotics cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.032 0.003 Mean (SD) 44220.0 (162117.4) 50776.9 (240245.1) 
Min, Max (0, 2388553) (0, 5092382) 
All inpatient 
admissions cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.094 0.000 Mean (SD) 1080756.8 (2981392.0 1413734.3 (4009021.2 
Min, Max (0, 42545150) (0, 53905540) 
LRTI-related 
inpatient 
admissions cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.082 0.008 Mean (SD) 400329.1 (1384010.9) 556818.8 (2333827.1) 
Min, Max (0, 17986500) (0, 43951550) 
Asthma-related 
inpatient 
admissions cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.083 0.009 Mean (SD) 231313.7 (894824.1) 310212.2 (999326.8) 
Min, Max (0, 17986500) (0, 9598590) 
Asthma 
exacerbation-
related inpatient 
admissions cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.077 0.011 Mean (SD) 80620.4 (525353.4) 126415.0 (662497.1) 
Min, Max (0, 9824000) (0, 6845720) 
All outpatient 
attendances cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.075 0.006 Mean (SD) 849514.9 (1323000.9) 948336.6 (1314429.2) 
Min, Max (34630, 24945790) (66520, 24875180) 
LRTI-related 
outpatient 
attendances cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.075 0.006 Mean (SD) 849514.9 (1323000.9) 948336.6 (1314429.2) 
Min, Max (34630, 24945790) (66520, 24875180) 
Asthma-related 
outpatient 
attendances cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.064 0.001 Mean (SD) 161057.6 (203547.9) 173403.4 (180851.7) 
Min, Max (0, 2503440) (0, 1662900) 
N (% not missing) 1926 (100.0) 642 (100.0) 0.072 0.001 
 Measure DPI Repeat Cohort pMDI Change Cohort SMD RCC 
All emergency 
attendances cost 
(KRW) 
Mean (SD) 409354.5 (1665530.6) 557420.3 (2401452.0) 
Min, Max (0, 38557320) (0, 42381850) 
LRTI-related 
emergency 
attendances cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.072 0.001 Mean (SD) 409354.5 (1665530.6) 557420.3 (2401452.0) 
Min, Max (0, 38557320) (0, 42381850) 
Asthma-related 
emergency 
attendances cost 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.062 0.008 Mean (SD) 100572.5 (508245.2) 138370.1 (700243.9) 
Min, Max (0, 6275700) (0, 9598590) 
All 
hospitalisation 
costs (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.103 0.004 Mean (SD) 2339626.2 (4670337.0) 2919491.2 (6423627.0) 
Min, Max (34630, 81897370) (66520, 97633700) 
All asthma-
related 
hospitalisation 
costs (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.108 0.012 Mean (SD) 1339489.7 (2316099.3) 1632171.9 (3035750.1) 
Min, Max (34630, 39352220) (66520, 43728160) 
Drug costs 
(without ICS) 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.040 0.002 Mean (SD) 330440.9 (392849.1) 314898.9 (380439.4) 
Min, Max (0, 4045468) (0, 5260946) 
Drug costs (with 
ICS) (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.121 0.020 Mean (SD) 714492.2 (532256.0) 652466.5 (494072.0) 
Min, Max (75807, 4686823) (100040, 5584425) 
Total costs 
(without ICS) 
(KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.096 0.013 Mean (SD) 1669930.6 (2480644.4) 1947070.7 (3259219.6) 
Min, Max (42150, 39881473) (72455, 48989106) 
Total costs (with 
ICS) (KRW) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.079 0.012 Mean (SD) 2053981.9 (2531746.3) 2284638.4 (3289058.6) 
Min, Max (149974, 40056081) (220157, 49312585) 
* RCC based on primary outcome of no exacerbations 
  
Table A9: Detailed results outcome 3 
 Measure 
DPI Repeat 
Cohort 
pMDI Change 
Cohort 
Unadjusted 
OR (95%CI) 
Adjusted 
OR (95%CI) 
Adjusted p-
value 
Severe 
exacerbations 
(ATS/ERS) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.88 (0.731, 
1.06)† 
0.788 
(0.651, 
0.954)† 
0.015† 
Mean (SD) 1.1 (2.4) 1.0 (2.3) 
Median (IQR) 0 (0, 1) 0 (0, 1) 
Min, Max (0, 26) (0, 39) 
Severe 
exacerbations 
(ATS/ERS) 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
Data visualisation only 
0, n (%) 1144 (59.4) 379 (59.0) 
1, n (%) 347 (18.0) 121 (18.8) 
2, n (%) 154 (8.0) 68 (10.6) 
3, n (%) 91 (4.7) 23 (3.6) 
≥4, n (%) 190 (9.9) 51 (7.9) 
Acute 
respiratory 
events 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.919 (0.795, 
1.063)† 
0.84 (0.728, 
0.971)† 0.018
† 
Mean (SD) 1.7 (2.8) 1.6 (2.7) 
Median (IQR) 1 (0, 2) 1 (0, 2) 
Min, Max (0, 27) (0, 39) 
Acute 
respiratory 
events 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
Data visualisation only 
0, n (%) 885 (46.0) 297 (46.3) 
1, n (%) 401 (20.8) 133 (20.7) 
2, n (%) 199 (10.3) 74 (11.5) 
3, n (%) 136 (7.1) 46 (7.2) 
≥4, n (%) 305 (15.8) 92 (14.3) 
Risk domain 
asthma control 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.959 (0.761, 
1.209)∆ 
1.157 (0.9, 
1.487)∆ 0.255
∆ No, n (%) 1095 (56.9) 369 (57.5) 
Yes, n (%) 831 (43.1) 273 (42.5) 
Overall asthma 
control 
N (% not missing) 1926 (100.0) 642 (100.0) 
1.041 (0.822, 
1.317)∆ 
1.221 (0.95, 
1.57)∆ 0.120
∆ No, n (%) 1178 (61.2) 389 (60.6) 
Yes, n (%) 748 (38.8) 253 (39.4) 
Asthma 
exacerbation-
related 
N (% not missing) 1926 (100.0) 642 (100.0) 
1.737 (0.902, 
3.345)† 
1.033 
(0.596, 
1.788)† 
0.909† Mean (SD) 0.0 (0.3) 0.1 (0.5) 
Median (IQR) 0 (0, 0) 0 (0, 0) 
 Measure 
DPI Repeat 
Cohort 
pMDI Change 
Cohort 
Unadjusted 
OR (95%CI) 
Adjusted 
OR (95%CI) 
Adjusted p-
value 
inpatient 
admissions Min, Max (0, 6) (0, 10) 
Asthma 
exacerbation-
related 
inpatient 
admissions 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
Data visualisation only 
0, n (%) 1878 (97.5) 616 (96.0) 
1, n (%) 35 (1.8) 19 (3.0) 
2, n (%) 4 (0.2) 4 (0.6) 
3, n (%) 5 (0.3) 1 (0.2) 
≥4, n (%) 4 (0.2) 2 (0.3) 
SABA inhaler 
average daily 
dose, µg 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.781 (0.671, 
0.909)‡ 
0.713 
(0.606, 
0.840)‡ 
<0.001‡ 
0, n (%) 1302 (67.6) 466 (72.6) 
>0-200, n (%) 358 (18.6) 108 (16.8) 
>200-400, n (%) 127 (6.6) 30 (4.7) 
>400-800, n (%) 77 (4.0) 27 (4.2) 
>800, n (%) 62 (3.2) 11 (1.7) 
Oral thrush 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.75 (0.251, 
2.243)∆ 
0.768 
(0.252, 
2.343)∆ 
0.215∆ No, n (%) 1910 (99.2) 638 (99.4) 
Yes, n (%) 16 (0.8) 4 (0.6) 
ICS average 
daily dose, µg 
(categorised) 
N (% not missing) 1926 (100.0) 642 (100.0) 
1.565 (1.353, 
1.809)‡ 
1.41 (1.212, 
1.641)‡ <0.001
‡ 
>0-250, n (%) 901 (46.8) 251 (39.1) 
>250-500, n (%) 728 (37.8) 220 (34.3) 
>500, n (%) 297 (15.4) 171 (26.6) 
Treatment 
stability 
N (% not missing) 1926 (100.0) 642 (100.0) 
0.947 (0.753, 
1.191)∆ 
1.1 (0.861, 
1.404)∆ 0.580
∆ No, n (%) 1106 (57.4) 374 (58.3) 
Yes, n (%) 820 (42.6) 268 (41.7) 
∆ Conditional binary logistic regression; ‡ Conditional ordinal logistic regression; † Conditional Poisson 
regression; N/A, not applicable; Severe exacerbations adjusted for LTRA prescriptions (categorised) and SAMA 
prescriptions (categorised); Acute respiratory events adjusted for LTRA prescriptions (categorised) and 
antibiotic prescriptions (categorised); Risk domain asthma control and overall asthma control both adjusted for 
LTRA prescriptions (categorised), antibiotic prescriptions (categorised) and other lung diseases ever; Asthma 
exacerbation-related inpatient admissions adjusted for SAMA prescriptions (categorised), LABA inhaler 
prescriptions, LTRA prescriptions and ICS prescriptions (yes/no indicator); SABA inhaler average daily dose 
adjusted for SAMA prescriptions (categorised), COPD diagnosis ever, LABA inhaler prescriptions (categorised); 
Oral thrush adjusted for influenza diagnosis ever, ICS prescriptions (yes/no indicator) and SAMA prescriptions 
(categorised); ICS average daily dose adjusted for LTRA prescriptions, SAMA prescriptions (categorised) and 
LABA inhaler prescriptions (yes/no indicator); Treatment stability adjusted for antibiotic prescriptions, LTRA 
prescriptions (yes/no indicator) and other lung diseases (ever) 
Appendix Transfform HIRA 
Appendix 1: Outcome specific inclusion criteria 
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Appendix 2: Clinical effectiveness outcomes 
 
i. Severe asthma exacerbation rate (ATS/ERS statement definition 2015), defined as 
an occurrence1 of the following: 
• Asthma exacerbation -related hospital admission OR 
• LRTI-related A&E attendance OR 
• LRTI-related acute oral corticosteroid course 
 
ii. Acute respiratory event, defined as an occurrence of the following: 
• Asthma exacerbation-related hospital admission OR 
• LRTI-related A&E attendance OR 
• LRTI-related acute oral corticosteroid course OR 
• LRTI-related antibiotics 
 
iii. Risk domain asthma control (RDAC) defined as absence of: 
• Asthma exacerbation-related hospital admissions AND 
• LRTI-related A&E attendance AND 
• LRTI-related acute oral corticosteroid course AND 
• LRTI-related antibiotics 
 
iv. Overall asthma control (OAC) 
• RDAC as defined above AND 
• ≤200μg salbutamol/≤500μg terbutaline average daily dose  
 
v. Treatment stability, defined as: 
• RDAC as defined above AND 
• No additional or change in therapy as denoted by 
o an increase in ICS dose of ≥50% of that of prescribed at index date AND/OR 
o addition of theophylline or LTRA or LABA 
 
vi. Asthma exacerbation-related hospitalisation rate, defined as: 
• Rate of asthma exacerbation-related hospital inpatient admissions 
 
vii. Average daily SABA usage: 
• Average daily SABA dosage during outcome year (in μg) calculated by 
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖ℎ𝑎𝑎𝑎𝑎𝑁𝑁𝑁𝑁𝑎𝑎 ∗ 𝑑𝑑𝑜𝑜𝑎𝑎𝑁𝑁𝑎𝑎 𝑝𝑝𝑁𝑁𝑁𝑁 𝑖𝑖𝑖𝑖ℎ𝑎𝑎𝑎𝑎𝑁𝑁𝑁𝑁365 ∗ 𝑎𝑎𝑠𝑠𝑁𝑁𝑁𝑁𝑖𝑖𝑠𝑠𝑠𝑠ℎ 
• Categorised as >0 to ≤200, >200 to ≤400, >400 to ≤800, >801 μg daily SABA 
dosage 
 
viii. Average daily ICS dose 
• Average daily ICS (fluticasone-equivalent) dosage during outcome year (μg) 
calculated by 
                                                          
1 Where ≥1 oral corticosteroid course/hospital inpatient/hospital outpatient/hospital emergency occurs 
within 7 days of each other, these events will be considered the result of the same exacerbation (and 
will only be counted once).  
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖ℎ𝑎𝑎𝑎𝑎𝑁𝑁𝑁𝑁𝑎𝑎 ∗ 𝑑𝑑𝑜𝑜𝑎𝑎𝑁𝑁𝑎𝑎 𝑝𝑝𝑁𝑁𝑁𝑁 𝑖𝑖𝑖𝑖ℎ𝑎𝑎𝑎𝑎𝑁𝑁𝑁𝑁365 ∗ 𝑎𝑎𝑠𝑠𝑁𝑁𝑁𝑁𝑖𝑖𝑠𝑠𝑠𝑠ℎ 
• Categorised as 0, >0 to ≤250, >250 to ≤500, >500 μg daily ICS dosage (low, 
medium, high as per GINA guidelines) 
 
ix. Incidence of oral thrush: 
• Diagnostic code for oral thrush OR 
• Prescription of antifungal therapy 
  
Appendix 3: Statistical tests used 
[TABLE A2] 
 
  
Appendix 4: Detailed statistical and analyses plan 
 
Sample size calculations 
Outcome 1: Persistence of change  
A previous study conducted by RiRL UK on the persistence of change from one ICS/LABA 
pMDI to a different ICS/LABA pMDI was used to inform the following power calculations for 
the 6-month outcome period. This assumed that changing inhalers is due to cost reasons 
rather than clinical reasons. It also assumed that the change from a pMDI to a different pMDI 
had a similar level of satisfaction to the change from a DPI to a pMDI. In reality, a change for 
clinical reasons is less likely to result in satisfaction, similarly a change to an inhaler that 
needs radically different technique is less likely to be met with satisfaction. 
Based on an expected “change-back” probability of approximately 0.20 (20%) among 
patients changing from existing ICS/LABA DPI to ICS/LABA pMDI at their prescription date, a 
sample size of 100 patients per change cohort was sufficient to construct a 95% one-sided 
confidence interval with an upper bound of less than 0.30 (30%) to power the evaluation of 
ICS/LABA pMDI “persistence of change”.  
 
Outcome 2: Non-inferiority of no exacerbations pre vs post change  
Non-inferiority of the proportion of patients with no exacerbations was tested between the 
outcome and the baseline periods within the persistence of change cohort. As such, 163 
patients were required based on the following calculation:  
When the sample size is 163, a paired McNemar’s Chi-square test with a 0.025 one-sided 
significance level has 90% power to reject the null hypothesis that the proportions are non-
inferior (i.e. the difference in proportions of “no exacerbations”, outcome-baseline, is 0.125 or 
farther from zero in the same direction) when the expected difference in proportions is 0.0, 
assuming that the proportion of discordant pairs is 0.242 (based on previous RiRL UK 
research). 
Outcome 3: Non-inferiority of no exacerbations pMDI vs DPI  
When the sample sizes in the groups are 208 and 208, a two-group large-sample normal 
approximation test of proportions with a one-sided 0.025 significance level has a 90% power 
to reject the null hypothesis that the proportions are non-inferior (the difference in proportions, 
ICS/LABA pMDI - ICS/LABA DPI is -0.10 or farther from zero in the same direction) in favour 
of the alternative hypothesis that the proportions in the two groups are equivalent, assuming 
that the expected difference in proportions is 0.033 and the proportion in the standard group is 
0.758 (based on RiRL UK study). 
Superiority 
A two-group continuity corrected χ2 test with a 0.05 one-sided significance level has 90% 
power to detect the difference between a ICS/LABA pMDI proportion, π1, of 0.791 and a 
ICS/LABA DPI proportion, π2, of 0.758 (odds ratio of 0.590) when the sample sizes are 1062 
and 1062, respectively (a total sample size of 2123). These numbers were also based on the 
RiRL UK study (79.1% exacerbation free on FLUTIFORM® vs 75.8% exacerbation-free on 
SERETIDE®). 
Non-inferiority versus superiority 
Following successful testing of non-inferiority, we also planned to examine superiority. 
Numbers were therefore calculated so as to be sufficient to allow for both non-inferiority and 
superiority testing. 
Baseline characterisation 
A characterisation of all baseline demographics, co-morbidities, indicators of disease severity 
and other patient characteristic variables was carried out and is presented for each arm. The 
following definitions were used: 
Demographics (at index date) 
• Age (years) 
• Gender (male/female) 
• Type of insurance (medical insurance, medical aid, veterans cover) 
 
Comorbidities (1-year baseline and ever) 
• COPD (KCD-6: J43-J44) 
• Tuberculosis (KCD-6: A15-A16) 
• Bronchiectasis (KCD-6: J47) 
• Diffuse panbronchiolitis (KCD-6: J21.9) 
• Interstitial lung disease (KCD-6: J84) 
• Lung cancer (KCD-6: C34) 
• Oral thrush (KCD-6: B37) 
• Actively treated eczema (KCD-6: L20, L30)  
• Gastro-oesophageal reflux disease (GERD) (KCD-6: K21)  
• IHD (KCD-6: I20-I25) 
• Influenza (KCD-6: J09-J12) 
• Other lung disease (KCD-6: J40, J41, J42, J60-J70, J84) 
• Nasal Polyps (KCD-6: J33)  
• Pneumonia (KCD-6: J13-J18)  
• Actively treated allergic and non-allergic rhinitis (KCD-6: J30, J31.0) 
• Charlson comorbidity index score2 (CCI) score  
                                                          
2 Based on the International Classification of Diseases, 10th revision (ICD-10) adapted to Korean 
Classification of Diseases, 6th revision (KCD-6). Predicts the ten-year mortality for patients with 
comorbidities, where each comorbidity is assigned a score. Sundararajan, Vijaya et al. "New ICD-10” 
Version of The Charlson Comorbidity Index Predicted In-Hospital Mortality". Journal of Clinical 
Epidemiology 57.12 (2004): 1288-1294 
 Disease severity and control (1-year baseline) 
• Number of all/LRTI-related3/asthma-related4/asthma exacerbation-related5 
hospitalisations 
• Number of all/LRTI-relatedd/asthma-relatede hospital outpatient attendances 
• Number of all/LRTI-relatedd/asthma-relatede emergency attendances 
• LRTI-relatedd acute6/non-acute oral corticosteroid course  
• LRTI-relatedd antibiotics7 
• Average SABA inhaler daily dose 
• Average SABA nebuliser daily dose 
• Average ICS daily dose  
• Number of severe asthma exacerbations  
• Number of acute respiratory events  
 
Medication (1-year baseline) 
• FDC ICS/LABA  
• Inhaled corticosteroids (ICS)  
• Intravenous/Intramuscular corticosteroids (IV/IM CS) 
• Short-acting beta agonist (SABA) inhaler/oral/nebuliser 
• Short-acting muscarinic antagonist (SAMA)  
• FDC SABA/SAMA   
• Long-acting beta agonist (LABA) inhaler/oral/patch 
• Long-acting muscarinic antagonist (LAMA)  
• FDC LABA/LAMA  
• Leukotriene Receptor Antagonist (LTRA)  
• Theophylline or other methylxanthines  
 
Health care costs (1-year baseline) 
• Prescriptions for asthma medication (specified under ‘Medication (1-year baseline) 
• Respiratory-related hospital costs: inpatient hospitalisation costs; outpatient 
attendance costs; and Accident & Emergency attendance costs 
 
The difference between the arms is quantified using the Standardised Mean Difference 
(SMD). This measure is not affected by the number of observations, and thus a better way to 
judge imbalance than a p-value of a hypothesis test of difference. The SMD was calculated 
                                                          
3 LRTI-related defined as: A lower respiratory tract infection (LRTI) diagnosis [whooping cough (A37), 
influenza (J09-J12), pneumonia (J13-J18), bronchitis (J20-22, J40)], OR asthma (J45– J46, J82) OR 
respiratory diagnosis [respiratory failure (J96), disorders of breathing (R06)] 
4 Asthma-related defined as: a diagnosis of asthma (J45– J46, J82) AND a prescription of any asthma 
medication (inhalers, OCS, Theophylline or LTRA) during visit/hospitalisation 
5 Asthma exacerbation-related defined as: a diagnosis of asthma (J45– J46, J82) AND a prescription 
of OCS or antibiotics during the visit/hospitalisation 
6 Acute oral corticosteroid use associated with asthma exacerbation treatment defined as: oral 
corticosteroid prescription of >10mg Prednisolone-equivalence with a duration of prescription ≥3 days 
7 Antibiotics use associated with asthma exacerbation treatment defined as: antibiotics prescription ≥7 
days 
for both continuous and categorical variables as described below: an SMD ≤0.1 indicates 
sufficient balance between the treatment and the reference (control) groups. 
[TABLE A3] 
 
Bias potential 
Bias potential assesses the degree to which the observed association between the exposure 
of interest and the outcome is affected by conditioning on the variable. Bias potential was 
measured using the relative change in co-efficient (RCC) of the exposure when the covariate 
is added into the model predicting outcome.  
[TABLE A4] 
 
It is called bias potential since the bias was estimated without other covariates in the model. 
To what extent a variable introduces bias into a model will depend on the total model. The 
baseline variables with the highest bias potential, that were also sufficiently imbalanced 
(SMD > 0.10) were presented to the steering committee for the final selection of variables 
that were used for matching. 
 
Matching process 
Exact matching for categorical variables and matching within a maximum caliper (maximum 
distance allowed between a case and a control) for continuous variables was used to match 
patients using nearest neighbour variable mixed matching, with a match maximum of 3:1 
without replacement. Mixed matching is a process that helps utilise more of the data by 
matching varying numbers of control arm patients to a treatment arm patient. In other words, 
a cohort of unique patients was matched 1:1, another cohort of unique patients was matched 
1:2, and a third cohort of unique patients was matched 1:3. The analysis was then conducted 
using all matched patients, even though some patients had 1 match while other patients may 
have had 3 matches. 
In cases of repeated measurements for a patient, only one record could contribute to the 
matching. Matching was repeated several times using a different patient sequence to select 
the run that resulted in the highest number of patients and/or the best baseline balance. The 
actual number of variables used for matching depended upon the degree of restriction caused 
by the matching process.  
Missing data was treated as missing completely at random and not imputed. If a selected 
confounder had more than 20% of missing data, it was not used for matching. If missingness 
was below 20%, the variable was encoded into a categorical variable, adding a category for 
the observations with missing values, enabling this variable to be used for matching. 
Based on the standardised mean difference (SMD) and clinical judgement, patients were 
matched based on baseline variables of age, gender, COPD diagnosis, categorised SABA 
inhaler average daily dose, categorised ICS inhaler average daily dose and categorised ATS 
exacerbation. Patients were then randomly picked with a maximum of 1:3 matching. The final 
cohort consisted of 642 FDC ICS/LABA pMDI patients and 1926 FDC ICS/LABA DPI patients.  
Post-matching evaluation 
Matching variables and confounder identification was conducted using the standardised mean 
difference (SMD) as a better measure of difference between cohorts instead of correlation 
measures. Bias potential in terms of relative change in co-efficient (RCC) of the exposure was 
also used in modelling and confounder identification to provide a measure of extent a variable 
introduces bias into a model. In order to not only rely on statistical differences, we also asked 
a panel of experienced clinicians to judge whether there remained any clinical relevant 
differences after SMD assessment. 
 
Statistical analyses 
Conditional regression analysis was performed on the matched dataset, taking into account 
the matched pairs. The type of regression used was dependent upon the outcome, linear 
regression for a continuous outcome, logistic regression for a binary outcome, Poisson 
regression for rates and proportional hazards regression for a time-to-event outcome. 
Adjustment for variables with residual confounding was made.  
Since it can be expected that these variables have similar associations with exposure and/or 
outcome their conditional bias on the variables already in the model was assessed. Starting 
with a model with exposure as the only explanatory variable, the variables were added one by 
one in order of their individual bias potential, highest first. After a variable was added to the 
model it was kept in if it caused the largest change-in-estimate (at least 2%) and a maximum 
change-in-standard error (less than 2%) relative to the prior model. The variable that caused 
the largest change-in-estimate was kept.  
Persistence of change  
The percentage of ICS/LABA pMDI patients who received ≥1 prescription of ICS/LABA pMDI 
(in addition to that issued at their prescription date) and no ICS/LABA DPI at 6 months was 
used to evaluate ICS/LABA pMDI “persistence of change”. Sub-analyses were performed to 
assess the number of patients remaining on the same drug and pMDI device. One-sided 90% 
confidence intervals for binomial proportions were calculated for all Phase 1 analyses. 
Non-inferiority of no exacerbations pre vs post change (Outcome 2) 
Conditional linear regression was used to obtain the non-inferiority limit of mean difference in 
patient proportions with no exacerbations. Non-inferiority was claimed if the lower limit of the 
95% CI of the mean difference in patient proportions with no exacerbations, outcome – 
baseline ≥-0.125. 
Conditional logistic regression was used to compare the proportion of patients with “no 
exacerbations” for within cohort (baseline vs outcome of persistence of change cohort) 
comparisons. 
Non-inferiority of no exacerbations pMDI vs DPI (Outcome 3) 
Conditional linear regression was used to obtain the non-inferiority limit of mean difference in 
patient proportions with no exacerbations. Non-inferiority was claimed if the lower limit of the 
95%CI of the mean difference in patient proportions with no exacerbations, pMDI change 
cohort – DPI repeat cohort ≥ -0.10. 
Conditional logistic regression was used to compare the proportion of patients with “no 
exacerbations” for cohort (persistence of change cohort vs DPI continuation cohort) 
comparisons. 
Secondary outcomes  
Conditional logistic regression, conditional Poisson regression and conditional ordinal logistic 
regression were used, as appropriate, to analyse the secondary effectiveness outcomes in 
outcome 2 and 3.  
Cost outcomes 
Cost outcomes were conducted for outcome 3 with comparisons made for asthma-related 
costs during the outcome year for the pMDI change cohort versus the DPI continuation 
cohort. Summary costs were compared between the matched pMDI change and continuation 
cohorts (outcome periods) using conditional linear regression.  
  
Appendix 5: Outcome 1 detailed results 
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Appendix 6: Outcome 2 detailed results 
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Appendix 7: Outcome 3 detailed results 
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Figure legends 
 
[FIGURE A1] 
Figure A1: Consort diagram outcome 1 
 
[FIGURE A2] 
Figure A2: Consort diagram outcome 2 
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Figure A3: Consort diagram outcome 3 
All patients with FDC ICS/LABA pMDI prescriptions n = 167,789
Not aged between 12 and 80 years;                                       
n = 13,234
Aged from 12 to 80 years at date of change n = 154,555 Patients with exclusion diagnosis;                               
n= 10,583          (lung cancer = 359, tuberculous =1417, interstitial        
lung disease = 1450, bronchiectasis = 9836)
Patients with no exclusion diagnosis n = 143,972
No asthma diagnosis; n = 11,526
Patients with asthma diagnosis n = 132,446 Patients with pMDI prescribed at baseline;                   
n = 36
Patients with no pMDI prescribed at baseline n = 132,410 Patients with <2 DPIs prescribed at                    
baseline;  n = 117,848
Patients with ≥2 DPIs prescribed at baseline n  = 14,562
Patients with maintenance OCS         
prescribed; n = 2847
Patients with no maintenance OCS prescribed n  = 11,715
Patients with multiple FDC at switch date                                            
n = 426
Patients with no multiple FDC at change date  n = 11,289
Patients with ICS at change date; n = 730
Patients with no ICS at change date n = 10,559
Patients with LABA at change date; n = 40 
Patients with no LABA at change date n =10,519
Different ICS GINA  category (last-recorded 
baseline vs index date); n = 7337
Same ICS GINA category (last-recorded baseline vs index date) n = 3182
Patients with less than 1 –year baseline           
data; n = 315
Patients with 1-year baseline data n = 2867 
Patients with less than 6-months outcome      
data; n = 481
Patients with 6-months outcome data n= 2386
Patients with  <1 FDC ICS/LABA in            
outcome; n = 395
Patients with ≥1 FDC ICS/LABA in outcome n =  1991
First possible repeat date within study period n = 1991 
Patients in pMDI change cohort n = 1991
All patients with FDC ICS/LABA pMDI prescriptions n = 167,789
Not aged between 12 and 80 years;                                       
n = 13,234
Aged from 12 to 80 years at date of change n = 154,555
Patients with exclusion diagnosis;                               
n= 10,583   (lung cancer = 359, tuberculous =1417, interstitial        
lung disease = 1450, bronchiectasis = 9836)
Patients with no exclusion diagnosis n = 143,972
No asthma diagnosis; n = 11,526
Patients with asthma diagnosis n = 132,446
Patients with pMDI prescribed at baseline;                   
n = 36
Patients with no pMDI prescribed at baseline n = 132,410
Patients with <2 DPIs prescribed at                  
baseline;  n = 117,848
Patients with ≥2 DPIs prescribed at baseline n  = 14,562
Patients with maintenance OCS         
prescribed; n = 2847
Patients with no maintenance OCS prescribed n  = 11,715 Patients with multiple FDC at change           
date; n = 426
Patients with no multiple FDC at change date  n = 11,289
Patients with ICS at change date; n = 730
Patients with no ICS at change date n = 10,559
Patients with LABA at switch date; n = 40 
Patients with no LABA at change date n =10,519
Different ICS GINA category (last-recorded 
baseline vs index date); n = 7337
Same ICS GINA category (last-recorded baseline vs index date) n = 3182
Patients with less than 1-year baseline            
data; n = 315
Patients with 1-year baseline data n = 2867 
Patients with less than 1- year                  
outcome data; n = 1023
Patients with 1-year outcome data n= 1844
Patients with  <1 FDC ICS/LABA in            
outcome; n = 1177
Patients with ≥1 FDC ICS/LABA in outcome n =  667
First possible repeat date not within study 
period; n = 0
First possible repeat date within study period n = 667 
Patients in pMDI change cohort n = 667
All patients with FDC ICS/LABA pMDI prescriptions 
Lost on Matching 
pMDI = 0, DPI = 0
Gender  
pMDI = 667, DPI = 141,275
Lost on matching 
pMDI = 0, DPI = 265
Age +/- 3 years 
pMDI = 667, DPI = 141,010
Lost on matching
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